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VIRTUAL CLINICAL TRIALS: ONE
STEP FORWARD, TWO STEPS BACK
LORI ANDREWS, KAYLA KOSTELECKY, STEPHANIE SPRITZ
AND ALEXANDRA FRANCO
Virtual clinical trials have entered the medical research landscape.
Today’s clinical trials recruit subjects online, obtain informed consent
online, send treatments such as medications or devices to the subjects’
homes, and require subjects to record their responses online. Virtual
clinical trials could be a way to democratize clinical research and
circumvent geographical limitations by allowing access to clinical research for people who live far from traditional medical research centers. But virtual clinical trials also depart dramatically from traditional medical research studies in ways that can harm individuals and
the public at large. This article addresses the issues presented by virtual clinical trials with regard to: (1) recruitment methods; (2) informed consent; (3) confidentiality; (4) potential risks to the subjects;
and (5) the safety and efficacy of treatments that are approved.
I. OVERVIEW
Medical research on human beings has consisted of triumphs1 and tragedies. Like other human endeavors, medical research has been characterized by
researchers’ capacity for brilliance and compassion at times, but also their baser
2
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1. See David Rose, A History of the March of Dimes, MARCH OF DIMES (Aug. 26, 2010),
http://www.marchofdimes.org/mission/a-history-of-the-march-of-dimes.aspx (explaining that through the
March of Dimes’ support, Salk’s research led to the breakthrough of a polio vaccine).
2. See The Tuskegee Timeline, CTRS. FOR DISEASE CONTROL AND PREVENTION,
http://www.cdc.gov/tuskegee/timeline.htm (last visited Oct. 18, 2016) (chronicling the Tuskegee experiments where black men with syphilis were not given treatment so that researchers could observe the natural course of the disease); see also, David S. Jones et al., Ethics and Clinical Research—The 50th Anniversary of Beecher’s Bombshell, 374 NEW ENG. J. MED. 2393, 2393–98 (2016) (arguing that “many
interests—medical, personal, political, military and commercial—have led researchers to conduct studies
they knew to be transgressive. It would be hubris to think that such lapses could not happen again”).
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emotions of racism,3 sexism,4 and avarice.5 Legal rules—in particular the U.S.
federal research regulations6—have been put into place to protect research participants and to ensure that the treatments that are approved are safe and effective.
But now ingenuity in another field—digital technology—is testing the ability of the research regulations to achieve their goals.7 Medical researchers have
started to recruit research subjects based on their online searches,8 social media
activities,9 and use of health apps.10 Rather than using an ad for a clinical trial in

3. See generally HARRIET WASHINGTON, MEDICAL APARTHEID: THE DARK HISTORY OF MEDICAL
EXPERIMENTATION ON BLACK AMERICANS FROM COLONIAL TIMES TO THE PRESENT 157 (2006) (tracing
systematic black oppression in medical science throughout American history and documenting abuse and
lack of proper notification or consent in experimentation decades before Tuskegee).
4. Rebecca Dresser, Wanted: Single, White Male for Medical Research, 22 HASTINGS CTR. REP. 24,
25 (1992) (explaining that women have been excluded from participation in biomedical studies due to
perceived weakness, denying them the benefit of such research).
5. See Kurt Eichenwald & Gina Kolata, Drug Trials Hide Conflicts for Doctors, N.Y. TIMES (May
16,
1999),
http://www.nytimes.com/1999/05/16/business/drug-trials-hide-conflicts-for-doctors.html?pagewanted=all&_r=0 (explaining that financial rewards caused doctors to place patients in research studies that were not appropriate for them).
6. See 45 C.F.R. § 46 (2015); see also 21 C.F.R. § 50 (2016).
7. Zachary Brennan, Industry Calls for More Guidance From FDA on New Clinical Trials Technology, RAPS (May, 11 2016), http://www.raps.org/Regulatory-Focus/News/2016/05/11/24930/Industry-Calls-for-More-Guidance-From-FDA-on-New-Clinical-Trials-Technology/.
8. E-Recruiting: Using Digital Platforms, Social Media, and Mobile Technologies to Improve Clinical Trial Enrollment, INVENTIV HEALTH, 10 (Oct. 14, 2013), http://www.inventivhealth.com/docs/e-Recruiting_Using_Digital_Platforms_Social_Media_and_Mobile_Technologies_to_Improve_Clinical_Trial_Enrollment.pdf.
9. Id.; Maloyre Allison, Can Web 2.0 Reboot Clinical Trials?, 27 NATURE BIOTECH. 895, 897
(2009) (detailing companies utilizing social media for clinical trial recruitment).
10. Roughly one-fifth of smartphone owners (nineteen percent) have health apps. Susannah Fox &
Maeve Duggan, Tracking for Health, PEW RES. CTR.–PEW INTERNET & AMERICAN LIFE PROJECT,
http://questromworld.bu.edu/grandchallenge/files/2013/03/PIP_TrackingforHealth_PDF, 11 (Jan. 28,
2013) http://www.digitaltrends.com/mobile/google-play-store-2014-most-downloaded-apps/ [hereinafter
Tracking for Health]. Industry estimates suggest that 50% of over 3.4 billion mobile device users will
have downloaded a health app by 2018. FOOD AND DRUG ADMINISTRATION, MOBILE MEDICAL
APPLICATIONS, http://www.fda.gov/medicaldevices/digitalhealth/mobilemedicalapplications/default.htm
(last updated Sept. 22, 2015). Even game apps can collect information that is revealing about someone’s
health. In some instances, the app or game or website is sponsored by a pharmaceutical company or biotechnology company seeking information for research. Wayne Usher & James Skinner, Health Websites
and Reliability Components, 55 ACHPER HEALTHY LIFESTYLES J. 29 (2008) (highlighting that websites
can collect health information when the page is sponsored by a pharmaceutical company or biotechnology
company seeking data for research); Micol Spinazzi, Human Behavior and the Health Information Search,
MAKOVSKY HEALTH, (Apr.l 24, 2014), http://www.makovsky.com/insights/blogs/m-k-health/44-insights/blogs/m-k-health/614-human-behavior-and-the-health-information-search (stating that for health
information searches, mobile use is up thirteen percent, while PC use is down fourteen percent over the
last year); Nicole May, Mobile Health Is App-le of Pharma’s Eye, PHARMAPHORUM.COM, (August 9,
2013), http://pharmaphorum.com/views-and-analysis/mobile-health-is-app-le-of-pharma-s-eye/ (explaining gamification of health apps could be focused on specific drugs or therapies); cf. Manhattan Research,
Few Pharma Websites Optimized for Mobile, According to Manhattan Research’s New ePharma Com-
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a local newspaper or paying a physician up to $5,000 to convince her patients to
participate in a clinical trial,11 the sponsor of a clinical trial can directly contact
potential research participants based on their digital data, such as someone who
did a Google search for “joint pain” or who “liked” the American Diabetes Association on Facebook.12
This digital transformation has not only changed the practices of researchers, it has changed the mindset of potential subjects. Clinical trial inquiries are
one of the top online searches for health information.13 Online services such as
TrialX—a free service that matches participants to relevant clinical trials based
on their health information14—use Twitter15 to match potential research subjects
to clinical trials that suit their needs: “all you need is to QuTweet (query tweets
pronounced cue-tweets) us at TrialX (@trialx), put in the keyword ‘CT’ (for
Clinical Trials) followed by your health profile.”16
Clinical trial recruiters first used the web to recruit subjects into traditional
research settings, asking the potential subject to travel to a university or research
center to participate.17 But, in 2011, a fundamental change occurred. The phar-

petitive Analysis Series, (Dec. 5, 2013), http://www.prnewswire.com/news-releases/few-pharma-websites-optimized-for-mobile-according-to-manhattan-researchs-new-epharma-competitive-analysis-series234601981.html (foreshadowing a push by pharmaceutical companies into the health app space). For a
listing of social media websites [and mobile apps] sponsored by pharmaceutical companies, see Mobile
App Wiki, DOSE OF DIGITAL, http://www.doseofdigital.com/healthcare-pharma-mobile-app-wiki/ (last
visited Sept. 28, 2016) (listing of mobile health applications sponsored by pharmaceutical companies);
Social Media Wiki , DOSE OF DIGITAL, http://www.doseofdigital.com/healthcare-pharma-social-mediawiki/ (last visited Sept. 28, 2016) (listing social media websites sponsored by pharmaceutical companies).
11. See Eichenwald & Kolata, supra note 5 (describing a recruitment effort in which Merck & Company offered a bonus to doctors who enrolled a quota of fourteen patients).
12. See generally Allison, supra note 9, at 900; cf. FRANK PASQUALE, THE BLACK BOX SOCIETY:
THE SECRET ALGORITHMS THAT CONTROL MONEY AND INFORMATION 28 (2015) (describing how an individual who conducts an online search for information on a disease, then later completes a seemingly
unrelated form, can land themselves on a targeted marketing list).
13. Allison, supra note 9, at 900.
14. Id.; see also Connecting Patients to Your Trials, TRIALX, http://trialx.com/iconnect/ (last visited
Sept. 13, 2016) (explaining that patients can search TrialX for clinical trials related to a specific condition
and contact the trial coordinator if they are interest in participating).
15. TrialX (@TrialX), TWITTER, https://twitter.com/trialx, (last accessed Sept. 7, 2016) (“Connecting patients to clinical research via trial finders, mobile research apps and more.”).
16. Trialx, CROSSOVER HEALTHCARE (Apr. 9, 2009), https://crossoverhealth.wordpress.com/com/#comment-894.
17. See, e.g., E-Recruiting: Using Digital Platforms, Social Media, and Mobile Technologies to Improve Clinical Trial Enrollment, supra note 8 (outlining practices for efficiently using social media to
identify potential research participants, tailor clinical trial messages by using “patient speak,” and target
potential participants); FRED HUTCHINSON CANCER RESEARCH CENTER, ACM NEWS, CLINICAL TRIALS
NOW USING SOCIAL MEDIA TO ATTRACT TRIAL PARTICIPANTS, (Mar. 24, 2010),
http://cacm.acm.org/news/80616-clinical- trials-now- using-social-media- to-attract- trial-participants/fulltext (describing the use of online advertisements to recruit participants for an HIV vaccine trial);
ABOUT MYCLINICALTRIALLOCATOR.COM, MCTL, http://www.myclinicaltriallocator.com/about/ (last
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maceutical company Pfizer received clearance from the Food and Drug Administration (FDA) to conduct a clinical trial entirely online.18 The Pfizer trial relied
on a process for conducting clinical trials over the internet patented by Boston
University19 and exclusively licensed to Mytrus, a clinical trials software company.20 Mytrus has since developed multiple technologies to support direct-topatient clinical trials, including an electronic informed consent system and remote data collection mechanisms.21
Online clinical trials were born of good intentions—to expand the opportunities for both researchers and participants.22 Virtual clinical trials have already
been conducted in which treatments have been tested, including for overactive
bladder and osteoarthritis.23 The treatments include medications,24 devices,25
and nutritional supplements.26

visited Jan. 16, 2017) (explaining that the purpose of the website is to search for clinical trials in a specific
geographic location).
18. Jennifer Corbett Dooren, A Clinical Drug Trial Via Phone, Computer, WALL ST. J. (June 7,
2011), http://www.wsj.com/articles/SB10001424052702304432304576369840721708396.
19. U.S. Patent No. 7,251,609 (filed Apr. 28, 2000).
20. See Mytrus Secures Exclusive Rights to Clinical-Trials Patent from Boston University, MYTRUS
(June 11, 2011), https://www.mytrus.com/en/news/detail/patent-rights; see also Mytrus Launches Pfizer
Trial, MYTRUS (June 8, 2011), https://www.mytrus.com/en/news/detail/wsj-pfizer (explaining that Mytrus
is supporting Pfizer’s study and holds the exclusive patent to conduct virtual clinical trials in the US).
21. MYTRUS, https://www.mytrus.com/en/products-services/direct-to-patient (last visited Jan. 15,
2017).
22. See Deborah Covington & Kristin Veley, The Remote Patient-Centered Approach in Clinical
Research, 24 APPLIED CLINICAL TRIALS 30, Feb./Mar. 2015 (explaining that online clinical trial can overcome geographic obstacles and increase research efficiencies).
23. See Web-Based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects
with
Overactive
Bladder
(REMOTE),
CLINICALTRIALS.GOV,
https://clinicaltrials.gov/ct2/show/NCT01302938 (last visited Jan. 22, 2017) (conducting a remotely controlled exploratory
clinical trial with internet based tools to study the effect of tolterodine on subjects with overactive bladder); see also Amp Orthopedics Initiates Clinical Trial in Knee Osteoarthritis Pain, MYTRUS (Dec. 7,
2011), https://www.mytrus.com/en/news/detail/amportho-oa [hereinafter Amp Orthopedics] (conducting
remote clinical study completely over a web-based medium to study the amelioration of knee pain in
patients with mild to moderate Osteoarthritis using non-thermal Pulsed Radio Frequency treatment); see
also Amp Orthopedics, Inc., Effectiveness Study of the Ivivi SofPulse for Pain Amelioration in Adults with
Mild
Knee
Osteoarthritis,
CLINICALTRIALS.GOV,
https://clinicaltrials.gov/ct2/show/study/NCT01457742?term=Ivivi&rank=1 (last visited Jan. 22, 2017).
24. Web-Based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects
with Overactive Bladder (REMOTE), supra note 23.
25. See
Mytrus
Ivivi
Osteoarthritis
Study,
YOUTUBE.COM,
(Aug.
7,
2013),
https://www.youtube.com/watch?v=42-_lda9RLE (advertising the Mytrus Ivivi Osteoarthritis study to
potential participants).
26. U.S. Patent No. 7,251,609 (filed Apr. 28, 2000). Timothy McAlindon et al., Effectiveness of Glucosamine for Symptoms of Knee Osteoarthritis: Results from an Internet-Based Randomized Double-Blind
Controlled Trial, 117 AM. J. MED. 643 (2004).
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The characteristics of “virtual clinical trials”27 are that they: (1) identify
potential participants by gathering data based on people’s online searches and
activities; (2) determine if people qualify for a trial (sometimes based on a medical record or X-ray, but sometimes based merely on the person’s self-report);
(3) obtain the individual’s consent over the internet; (4) send the participant the
treatment (drug or device) in the mail; (5) get the participant to report if the treatment is working; (6) pay the participant at various points for participating; and
(7) base the FDA approval and marketing decisions on those self-reports, or, in
some cases, laboratory measures of progress.28
This article examines virtual clinical trials in light of long-standing legal
and ethical obligations of researchers.29 Federal regulations require researchers
at institutions that receive federal funds to submit proposals for studies of human
subjects to Institutional Review Boards (IRBs) that evaluate such proposals

27. Throughout this paper, we will refer to “virtual clinical trial(s)” or “online medical research”
interchangeably when we are talking about the entirely remote clinical trials in which subjects are undergoing a clinical experiment at their home and over the internet. We will also use the terms “medical research trial” and “clinical trial” interchangeably.
28. See Covington & Veley., supra note 22, at 31 (explaining that many aspects of clinical trials can
be completed remotely, including recruitment, informed consent, reporting results, and payment); see also
Amp Orthopedics, supra note 23 (requiring potential participants to submit an x-ray that indicates knee
osteoarthritis to participate in the study); see also MYTRUS, Overactive Bladder Homepage, Sept. 24,
2011, https://web.archive.org/web/20110924121322/https://oab.mytrus.com/home (last visited Jan. 16,
2017 by searching for “oab.mytrus.com/home” in the Internet Archive’s Wayback Machine Index) (asking
potential participants whether they experienced urine leakage); see also Miguel Orri et al., Web-based
Trial to Evaluate the Efficacy and Safety of Tolterodine ER 4 mg in Participants with Overactive Bladder:
REMOTE Trial, 38 CONTEMPORARY CLINICAL TRIALS 193 (2014) (explaining that Pfizer obtained a
waiver from the FDA to ship the study drug to participants via overnight delivery); see also Frequently
Asked Questions about the FDA Drug Approval Process, FDA (Jan. 7, 2015),
http://www.fda.gov/Drugs/ResourcesForYou/SpecialFeatures/ucm279676.htm (last visited Sept. 14,
2016) (explaining that clinical trials allow the FDA to decide whether a drug should be approved for
marketing).
29. These duties include compliance with the Nuremberg Code, Federal Research Regulations, state
research laws, and medical ethics codes. NUERNBERG MILITARY TRIBUNALS VOL. II ,TRIALS OF WAR
CRIMINALS BEFORE THE NUREMBERG MILITARY TRIBUNAL UNDER CONTROL COUNCIL LAW NO. 10
181−82(U.S. Gov. Printing Office, Oct. 1946−Apr. 1949) (stating that basic principles must be met when
experimenting with human participants to satisfy moral, ethical and legal concepts); see also DHHS Protection of Human Subjects, 45 C.F.R. § 46 (2015); see also CAL. HEALTH & SAFETY CODE § 24170 (West
1978); see also, e.g., AMA Code of Medical Ethics, AM. MED. ASS., http://www.amaassn.org/ama/pub/physician-resources/medical-ethics/code-medical-ethics.page (last visited Jan. 16,
2017) (stating that physicians must gain voluntary consent from the participant, disclose risks of the study,
minimize any risks to the participant, and maintain confidentiality).
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based on their adherence to federal regulations for the protection of human subjects.30 The regulations provide that the risks to subjects be justified by the benefits that may result from the research,31 that voluntary informed consent be garnered,32 that confidentiality be maintained,33 and that vulnerable populations
receive additional special protections.34 Furthermore, any research to be used in
support of an application for drug approval to the FDA must comply with regulations protecting human subjects in federally-funded trials, even if the research
institutions do not receive federal grants.35 This expands the reach of the federal
regulations to pharmaceutical and biotechnology companies planning to market
new drugs and devices.36 The regulations are designed to protect research participants from risks and to ensure that, when a treatment is marketed, it is safe
and effective.37
Virtual clinical trials could be a way to democratize clinical research and
provide access to clinical research for people who live far from traditional medical research centers by breaking down geographical barriers that hinder their
participation.38 Such trials could also be more cost-effective than traditional research which takes place at a hospital, university, or other medical institution.39
But virtual clinical trials also depart dramatically from traditional medical research studies. This Article addresses several potential risks to the participants
and to society: (1) inappropriate recruitment methods; (2) informed consent concerns; (3) confidentiality issues; (4) potential risk to the subject; and (5) concerns
about the safety and efficacy of treatments that are approved. The article also
suggests ways in which these risks might be addressed through law.
Consider the following scenario: a teenager is solicited over the internet,
based on his social media comments or online searches, for a clinical trial of a
treatment of depression. He poses as an adult, submits the informed consent form
and is sent a six-week supply of pills. The sponsor adds money to his debit card
each time he fills in a form about how he is feeling each day. Nothing could stop
him from flushing the drugs down the toilet, saying the drugs are working, and
collecting his money. In addition, since many companies collect data about people’s activities on the web, the fact that he is in a depression research study could
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.

45 C.F.R. §§ 46.101(a), 46.102(h), 46.102(j), 46.103(b) (2015).
45 C.F.R. § 46.111(a)(2) (2015).
Id. § 46.111(a)(4).
Id. at (a)(7).
45 C.F.R. § 46.111(b) (2015).
See 21 C.F.R. § 50.1(a) (2016).
See id.
See 21 C.F.R. §§ 50.1(a) and 21 CFR § 99.201(a)(2) (2016).
See Covington & Veley, supra note 22, at 24.
See id. at 31. See Michael J. McFarland, Ethical Implications of Data Aggregation, SANTA
CLARA U.: MARKKULA CTR. FOR APPLIED ETHICS (June, 1, 2012), https://www.scu.edu/ethics/focus-areas/internet-ethics/resources/ethical-implications-of-data-aggregation/.
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be sold by data aggregators to third party institutions, such as employers and life
insurers, and used to discriminate against him. In the meantime, the potentially
dangerous drug could be approved based on “faked” data and a patient who takes
the drug could be harmed.
II. HOW DO VIRTUAL CLINICAL TRIALS WORK?
For a medical research trial to succeed, researchers must recruit and maintain an adequate number of participants for the duration of the study.40 An
astounding 19.8 million participants were needed globally for clinical trials in
2005; this figure has undoubtedly increased.41 As many as two-thirds of investigative sites are unable to recruit a sufficient number of participants.42 In fact,
one-third of investigative sites are unable to recruit even one participant.43 Even
the National Cancer Institute has trouble enrolling patients for clinical trials;
more than one in five trials it sponsored failed to enroll even one participant.44
Fewer than 20% of trials meet their deadline; half of the delays are due to difficulty recruiting participants.45
This great demand for research participants reflects the increase in clinical
research over the last twenty years, fueled in part by an increasing commercial
interest in developing pharmaceutical products.46 At the same time, other forces
40. Trudo Lemmens & Paul B. Miller, The Human Subjects Trade: Ethical and Legal Issues Surrounding Recruitment Incentives, 31 J.L. MED. & ETHICS 398, 400 (2003).
41. See VICKI ORANSKY WITTENSTEIN, FOR THE GOOD OF MANKIND?: THE SHAMEFUL HISTORY OF
HUMAN MEDICAL EXPERIMENTATION 60 (Twenty-First Century Books, 2014) (stating that the number of
participants needed for clinical trials rose from 2.8 million to 19.8 million between 1999 and 2005); cf.
Trends, Charts, and Maps, CLINCALTRIALS.GOV, https://clinicaltrials.gov/ct2/resources/trends#RegisteredStudiesOverTime (last visited Jan. 16, 2017) (showing that the number of registered clinical trials
rose from 24,921 to 207,083 between 2005 and 2015).
42. Press Release, Tufts Center for the Study of Drug Development, Drug Developers Actively Improving Efficiency of Clinical Trials (Apr. 26, 2011), http://csdd.tufts.edu/news/complete_story/rd_pr_apr_2011.
43. Allison, supra note 9, at 895.
44. Id. at 896.
45. Id. at 895.
46. Trudo, supra note 40. The top 15 pharmaceutical companies with the highest market earnings
combined made approximately $526 billion in profits in 2014. See Tracy Staton, The Top 15 Pharma
Companies by 2014 Revenue [hereinafter The Top 15], F IERCE P HARMA (Mar. 18, 2015),
http://www.fiercepharma.com/special-report/top-15-pharma-companies-by-2014-revenue; see also Who
Has the Biggest One? Sales of the Top Pharma Products by Revenue, PHARMACOMPASS (Apr. 23, 2015),
http://www.pharmacompass.com/radio-compass-blog/who-has-the-biggest-one-sales-of-the-top-pharmaproducts-by-revenue (explaining that T HE T OP 15 calculated revenue based on every division within the
companies analyzed, listing the following companies and their revenue in millions of dollars: Johnson &
Johnson — 74,331; Novartis — 57,996; Roche — 47,462; Pfizer — 49,605; Sanofi — 43,070; Merck —
42,237; GlaxoSmithKline — 39,960; AstraZeneca — 26,095; Bayer — 25,47; Gilead Science — 24,474;
Teva — 20,270; Amgen — 20,063; AbbVie — 19,960; Eli Lilly — 19,615; Bristol Myers Squibb —
15,879); see also Richard Anderson, Pharmaceutical Industry Gets High on Fat Profits, BBC N EWS
(Nov. 6, 2014) (listing similar revenue numbers and estimating that the top companies have profit
margins ranging from ten to forty-three percent.
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deter people from participating in research. The costs of participation, lack of
insurance coverage for experimental treatments in clinical trials, and distrust
arising as a result of past abuses of research subjects can deter enrollment in
clinical trials.47
This shortfall in participation is occurring at a time when people are increasingly turning to online search engines to find health information. The 2015
Rock Health Digital Health Consumer Survey found that 71 percent of adults in
the United States have searched online for health information.48 The survey also
found that 17 percent of the adult population is currently tracking a key health
factor in a mobile application.49
Drawing on the fact that people reveal their medical conditions on the web,
researchers began to use that information to recruit research subjects. In June
2011, the pharmaceutical company Pfizer began the first virtual clinical trial in
the U.S. under an investigational new drug application, with nearly every step of
the trial—from candidate screening to data reporting—completed remotely.50
The trial, Research on Electronic Monitoring of OAB [Overactive Bladder]
Treatment Experience, or REMOTE, involved a drug that had already been approved by the Food and Drug Administration for that condition.51
The goal was to recruit 600 participants for the REMOTE trial through targeted advertisements that appeared when internet users entered certain words
into search engines or social network sites and through banner advertisements on
47. See Paying for Clinical Trials, NIH, https://www.cancer.gov/about-cancer/treatment/clinical-trials/paying (last updated June 22, 2016) (describing the costs involved with participating in a cancer clinical trial); see also Janet Leah Richards, Geography is Destiny: Disparate Insurance Coverage for Cancer
Clinical Trials Demands a Federal Mandate, 76 U. MO -K.C. L. R EV . 141, 143, 144 (2007) (finding
that insurance carriers use policy exclusions deny claims for experimental treatment); see also Osagie K.
Obasogie, Prisoners as Human Subjects: A Closer Look at the Institute of Medicine’s Recommendations
to Loosen Current Restrictions of Using Prisoners in Scientific Research, 6 STAN. J. C.R. & C.L. 41, 72–
73 (2010) (noting the changing landscape in clinical trials along with isolated incidents has drastically
decreased public trust in clinical trials).
48. Malay Gandhi & Teresa Wang, Digital Health Consumer Adoption: 2015, ROCK HEALTH (2015),
http://rockhealth.com/reports/digital-health-consumer-adoption-2015/#survey-overview.
49. Id.
50. See Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects with Overactive Bladder (REMOTE), supra note 23; see also Press Release, PFIZER, Pfizer Conducts
First “Virtual” Clinical Trial Allowing Patients to Participate Regardless of Geography (June 7, 2011),
http://press.pfizer.com/press-release/pfizer-conducts-first-virtual-clinical-trial-allowing-patients-participate-regardless.
51. See Hannah Waters, FDA Approval Signals More ‘Homework’ on the Horizon in Trials, 17
NATURE MED. 754 (2011); see also Jennifer Ringler, Pfizer Asks Patients to Test Themselves,
P HARMA B LOG (June 14, 2011), http://iqpc-pharma.blogspot.com/2011/06/pfizer-asks-patients-to-testthemselves.html (describing that REMOTE would use cell phone and internet access to recruit and track
trial participants). Rachel E. Sherman, associate director for medical policy at the Center for Drug Evaluation and Research stated that the main reason for the study was to test the methodology of virtual clinical
trials. See Mike Mitka, Strategies Sought for Reducing Cost, Improving Efficiency of Clinical Research,
306 J. AM. MED. ASS’N, 364, 365 (2011) (providing a high level overview of the participant recruitment
process mapped for the REMOTE trial by startup company Mytrus).
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health websites.52 Those advertisements directed interested individuals to the
trial’s website,53 which promised eligible participants $25 payments for each
online assessment or lab visit, with the possibility of earning a maximum of
$175.54
The website, which was operated by the clinical trial software company
Mytrus, screened potential participants through a two-part online questionnaire
with basic questions such as, “Will you have access to the Internet for the next
16 weeks (the study period)?” and “During the last 3 months: Have you leaked
urine (even a small amount)?”55 After this initial questionnaire, researchers attempted to verify a participant’s identity by asking questions that “only [the potential participant] can answer” such as, “Select a street address you had in
1985,” “Select a hospital in which you were born,” and “Select a model of car
you owned in 1997,”56 and comparing the answers with public records databases.57
Upon completion of the initial part of the questionnaire, the website
prompted the participant to review and sign an electronic informed consent document with information about “the benefits and risks of the trial.”58 The informed consent document also included what Mytrus calls a “friendly” questionnaire, but the inability to answer questions correctly would not necessarily
preclude the person from participating in the study.59
Next, Mytrus would contact the individual and send a package that included
a debit card which would be filled with money after a participant completed
“each study milestone” and lab supplies for a blood draw that could be conducted

52. CLINPAGE, Pfizer’s Web Experiment: No Site? No PI? No Problem, (Apr. 5, 2011),
http://www.clinpage.com/article/no_site_no_pi_no_problem/C24.
53. Id.; see also MYTRUS, https://www.mytrus.com/ (last visited Jan. 22, 2017) (private company
conducting recruitment).
54. Peter Mansell, Pfizer Announces ‘Virtual Clinical Trial Pilot in US, PHARMATIMES (June 9,
2011), http://www.pharmatimes.com/news/pfizer_announces_virtual_clinical_trial_pilot_in_us_980906.
55. See Orri et al., supra note 28. (explaining how the web-based screening process worked during
the trial); see also Association ELA, Mytrus 16-wk Paid Overactive Bladder Clinical Trial for Women,
YOUTUBE
at
1:07
(Apr.
2011),
https://www.youtube.com/watch?v=AyaBYQyMQz8&list=PL1gonBvfnk1lEtILWBxAI0m9B7qTnyuNo&index=9 (describing the screening process with example screening questions in a video designed to attract potential participants).
56. See Orri et al., supra note 28 (explaining that screening included precautionary procedures to
confirm participant identities); Association ELA, supra note 55, at 1:15 (giving examples of questions
that may be asked to confirm the participant’s identity).
57. Pfizer’s Web Experiment: No Site? No PI? No Problem, supra note 52.
58. See Association ELA, supra note 55, at 1:24–1:30 (explaining that the informed consent contained information about the risks and benefits of the REMOTE trial); see also Orri et al., supra note 28,
at 193 (describing the informed consent process for the REMOTE trial).
59. See, Mytrus, Inc., Mytrus Enroll Introduction, YOUTUBE (May 8, 2014),
https://www.youtube.com/watch?v=1AqJWkYoOVs (advertising the Mytrus Enroll electronic informed
consent product); see also Orri et al., supra note 28, at 191, 192 (explaining the informed consent process
as it was conducted in the REMOTE trial).
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either “during a home visit or at a nearby designated lab.”60 Mytrus would send
the participants a digital diary device to “record urination volume and frequency
of urinations throughout the study.”61 At the conclusion of the trial, participants
received individual trial results for export into personal medical records.62
Remarkably, during this process, participants receive a package containing
enough of the drug to last 14 weeks without having to set foot inside a research
facility.63 Because this methodology was unprecedented, Pfizer had to obtain a
waiver from the FDA in order to send the drugs to the participants at their
homes.64
Other virtual clinical trials have been conducted using a similar methodology. One such trial tested the effectiveness of glucosamine and chondroitin sulfate in treating osteoarthritis.65 Researchers recruited participants through the
internet using links on health-related internet sites, such as the Arthritis Foundation’s webpage, and through advertisements in online publications unrelated to
health.66 Similar to the REMOTE trial, a potential participant who viewed the
study website and indicated interest in participation would be screened over the
internet by self-administered questionnaires.67 The screening questions included: “Do you get pain in one or both knees after walking 2-3 city blocks (~1/4
mile)?” and “Have you ever been diagnosed by a physician as having arthritis in
your knees?”68 The glucosamine and chondroitin sulfate would then be sent directly to the participants’ homes and participants would record their reaction on
an online form.69

60. See Association ELA, supra note 55, at 2:02–2:27 (describing the virtual overactive bladder clinical trial to potential participants).
61. Id. at 2:55–3:05.
62. See Pfizer Press Release, supra note 51; see also Association ELA, supra note 55, at 2:40, 3:003:05.
63. See Association ELA, supra note 55, at 2:36–2:46.
64. See Ringler, supra note 51 (reporting on Pfizer’s announcement of its new REMOTE clinical
trial). One year after starting the REMOTE trial, Pfizer stopped enrolling subjects. See Pfizer Ends Social
Media Bid for Trial Recruitment, BIOSPACE (June 2012), http://www.biospace.com/News/pfizer-incends-social-media-bid-for-trial/264338. Pfizer was ultimately not able to recruit enough people to participate in the study. See Nick Taylor, Pfizer Director Defends Virtual Trial After Recruitment Struggle,
OUTSOURCING-PHARMA.COM (Mar. 6, 2012), http://www.outsourcing-pharma.com/Clinical-Development/Pfizer-director-defends-virtual-trial-after-recruitment-struggle.
65. Tim McAlindon et al., Conducting Clinical Trials Over the Internet: Feasibility Study, 372 BMJ
484, 484 (2003).
66. U.S. Patent No. 7,251,609 col. 18, l. 58–67 (filed Apr. 28, 2000); see also McAlindon et al., supra
note 26, at 644.
67. U.S. Patent No. 7,251,609 col. 3, l. 3–15 (filed Apr. 28, 2000); see also McAlindon et al., supra
note 65, at 485.
68. U.S. Patent No. 7,251,609 col. 19, l. 23–28 (filed Apr. 28, 2000); see also McAlindon et al., supra
note 65, at 485.
69. U.S. Patent No. 7,251,609 col. 5, l. 47–60 (filed Apr. 28, 2000) (participants could also obtain
the supplements at a pharmacy or clinic); see also McAlindon et al., supra note 65, at 485.
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Devices, as well as drugs, have been mailed to research participants.
Mytrus enrolled patients for a virtual clinical trial, sponsored by Ivivi Health
Sciences, using an electromagnetic field therapy (EMF) device for the treatment
of osteoarthritis.70 The device emitted a pulsed magnetic field to reduce inflammation caused by osteoarthritis.71 The criteria for qualification in this study included submission of an X-ray of each knee taken at least twelve months preceding the study, self-reported constant knee pain in the two months preceding the
study in at least one knee, the ability to read and complete survey questionnaires
in English, and access to the internet on a daily basis.72 Mytrus’ website encouraged participation by exclaiming: “You’ll be glad to know we value your time.
Patients who choose to participate in the study will sent a special debit card, that
can be used anywhere that accepts normal debit cards. You may earn up to $200,
and payments will be automatically added to your card as you complete portions
of the study.”73
Mytrus collected information daily about how the participant was feeling
using standard pain scales and questionnaires.74 Mytrus would ask participants
questions such as: “How much knee pain are you experiencing today?” “Did you
sleep well last night?” and “How difficult is it to walk up a flight of stairs?”75
Mytrus finished the trial and anticipates that the results “could become the basis
for market clearance” of the device.76
Mytrus has expressed interest in conducting virtual clinical trials for binge
eating, chronic obstructive pulmonary disease, diabetes, sleeping disorders and
other maladies.77 In March 2016, Mytrus also announced that it would be providing the virtual trial infrastructure for the ADAPTABLE (Aspirin Dosing: A Pa-

70. See Amp Orthopedics, supra note 23 (announcing a direct-to-patient clinic trial in knee osteoarthritis pain that allows patients to participate in the study from their own homes); see also id. (explaining
that the purpose of the study is to evaluate the effectiveness of non-thermal pulsed radio frequency treatment for alleviating knee pain in patients with mild to moderate osteoarthritis); Mytrus Ivivi Osteoarthritis
Study, YOUTUBE (Aug. 7, 2013), https://www.youtube.com/watch?v=42-_lda9RLE (explaining the study
to potential trial participants).
71. See Amp Orthopedics, supra note 23 (testing non-thermal pulsed radio frequency will be used
for pain amelioration in adults with knee osteoarthritis); see also id (announcing a clinic trial that uses
non-thermal pulsed radio frequency technology to alleviate pain from knee osteoarthritis.); Mytrus Ivivi
Osteoarthritis Study, supra note 70, at 1:22. (explaining to potential participants that the study treatment
is given through knee wrap devices).
72. Amp Orthopedics, supra note 23.
73. Mytrus Ivivi Osteoarthritis Study, supra note 70.
74. Id.
75. Id. at 4:00.
76. Amp Orthopedics, supra note 23.
77. Wouter Stomp, Pfizer Integrating Telemedicine into Clinical Trials, MEDGADGET (June 15,
2011), http://www.medgadget.com/2011/06/pfizer-integrating-telemedicine-into-clinical-trials.html (noting that Mytrus has trials slated for “osteoarthritis, binge eating, COPD, diabetes, sleep disorders and
informed consent validation.”).
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tient-Centric Trial Assessing Benefits and Long-Term Effectiveness) trial conducted by the Duke Clinical Research Institute.78 The study plans to compare
the dosing effects of aspirin in 20,000 subjects diagnosed with atherosclerotic
cardiovascular disease.79
The virtual clinical trials model is being embraced by pharmaceutical companies, device companies, and even traditional research settings such as universities.80 But do the federal research regulations, drafted before the widespread
use of the internet, adequately protect either subjects or the public when a virtual
clinical trial is undertaken?
III. CONCERNS ABOUT ONLINE RECRUITMENT OF POTENTIAL RESEARCH
SUBJECTS
The federal research regulations provide little guidance about the recruitment of research subjects, whether in traditional or virtual trials.81 When the
regulations were enacted, it was expected that medical research subjects would
be recruited by their physicians, who owed independent ethical and legal obligations to their patients.82 In that scenario, physician intermediaries had the duty of

78. PCORI, COMPARING TWO ASPIRIN DOSES TO PREVENT HEART ATTACK AND STROKES IN
PEOPLE LIVING WITH HEART DISEASE: THE ADAPTABLE STUDY, https://www.pcori.org/research-results/2015/comparing-two-aspirin-doses-prevent-heart-attacks-and-strokes-people-living (last visited
Feb. 16, 2017) (Trial website stating that as of January 2017, the trial’s status is “In Progress-Not yet
recruiting”); see also, NIH, ASPIRIN DOSING: A PATIENT-CENTRIC TRIAL ASSESSING BENEFITS AND
LONG-TERM EFFECTIVENESS (ADAPTABLE), https://wwwcf.nlm.nih.gov/hsr_project/view_hsrproj_record.cfm?NLMUNIQUE_ID=20153384(National Institutes of Health website listing the ADAPTABLE
trial’s status as “Ongoing”).
79. Mytrus Technology Chosen for Precedent-Setting ADAPTABLE Aspirin Trial, MYTRUS (Mar. 7,
2016), https://www.mytrus.com/en/news/detail/20160307-dcri.
80. See Virtual Reality: Where Does the Clinical Trial Industry Go from Here?, CLINICAL TRIALS
ARENA (Aug. 12, 2015), http://www.clinicaltrialsarena.com/news/operations/virtual-reality-where-doesthe-clinical-trial-industry-go-from-here-4644601 (noting that the pharmaceutical companies Pfizer,
Sanofi, and Shire have each conducted at least one virtual clinical trial); see also Amp Orthopedics Initiates
Clinical
Trial
in
Knee
Osteoarthritis
Pain,
MYTRUS (Dec.
7,
2011),
https://www.mytrus.com/en/news/detail/amportho-oa (explaining that medical device manufacturer Amp
Orthopedics has conducted a virtual clinical trial for one of its products); see also Mytrus Technology
Chosen for Precedent-Setting ADAPTABLE Aspirin Trial, supra note 79 (noting that Duke Clinical Research Institute, an academic institution, is partaking in a virtual clinical trial).
81. Covington & Veley., supra note 22, at 24 (“There is little regulatory guidance on designing and
conducting remote patient centered studies.”).
82. Clinical Trials and Human Subject Protection, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/default.htm, (last visited
Feb. 20, 2018), (noting that regulations protecting human subjects in clinical trials have been in existence
since the 1970s); see also AM. MED. ASS’N. CODE MED. ETHICS § 7 (2016) (noting ethical and legal obligations of physicians recruiting patients for clinical trials, and for the general presumption that it is physicians who recruit patients for clinical trials); Moore v. Regents of the Univ. of Cal., 793 P.2d 479, 483
(Cal. 1990) (finding a legal cause of action when a physician who performed medical research on his
patient without informed consent breached his fiduciary duty to the patient).
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ensuring that participation in the trial was in the patient’s best interest83 and that
the patient had the capacity to give informed consent.84 Even when a physicianpatient relationship did not exist between the potential subject and the recruiter,
the clinical backgrounds of subject recruiters (such as nurses and doctors) ensured an awareness of the responsibility as medical professionals to protect individual welfare.85 Although health care professionals (especially those paid to
recruit patients into studies) did not always act in the patients’ best interests,86
patients did have recourse to lawsuits based on malpractice,87 lack of informed
consent88 or breach of fiduciary duty89 if the health care professional entered
them into inappropriate and risky research.
Online recruitment for clinical trials provides no such backstop to curtail
inappropriate enrollment. When trial recruitment occurs outside of the fiduciary
relationship between physician and patient, the ethical imperative of acting consistently with the patient’s best interest is removed.90 In place of a medical professional with a well-established ethical duty to patient wellbeing, a questionnaire is responsible for safeguarding individual interests.91 Even the most
beneficent questionnaire design will be crude in its assessment of patient best
interests, as patient interests cannot be inferred from information about a patient’s online profile alone. A patient who is harmed by enrollment in a study,
or who has not provided informed consent, may have limited legal recourse when
a trial is conducted virtually without the direct involvement of medical professionals.92 Legal causes of action that have traditionally protected trial partici-

83. AM. MED. ASS’N. CODE MED. ETHICS § 7 (2016) (noting the ethical obligation to protect the
participants’ interests).
84. See id. (requiring informed consent as an ethical obligation); see also A. D. Nieuw, Informed
Consent, 12 MED. L. 125, 125–26 (1993) (noting that there is a legal duty to provide informed consent).
85. See Kurt Eichenwald & Gina Kolata, supra note 5 (emphasizing the responsibility that privatepractice doctors conducting research feel toward trial participants).
86. See id. (describing instances in which doctors with financial stakes in recruiting participants recommended patients for trials that were inappropriate for them, such as a patient who was referred despite
a known heart condition that made him ineligible).
87. Karp v. Cooley, 493 F.2d 408, 423–24 (5th Cir. 1974) (noting in dicta the existence of a medical
malpractice cause of action for experimentation).
88. Moore v. Regents of the Univ. of Cal., 793 P.2d 479, 483 (Cal. 1990) (finding a cause of action
for performance of medical procedures without informed consent)
89. Id.
90. Id. (stating that when there is a physician-patient relationship, the physician is ethically bound to
disclose “personal interests unrelated to the patient’s health” because of the fiduciary relationship).
91. Id. at 483 (declaring that medical professionals are bound by ethical duties, when a physicianpatient relationship exists); see also Covington & Veley, supra note 22 (describing how potential virtual
clinical trial participants self-enroll online and submit trial data online, rather than through a doctor intermediary).
92. Id. (requiring a physician-patient relationship before finding medical malpractice liability in the
context of a clinical trial); see also Anthony Francis, Is This a Real Doctor-Patient Relationship?,
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pants, such as breach of fiduciary duty or malpractice, are grounded in the particularities of the clinical relationship and professional norms.93 As the virtual
trial is driven largely by private companies with no direct relationship to the patient, a harmed subject may be limited to causes of action such as breach of contract.94 Unlike causes of action that emerged in response to power imbalances
between patients and the medical establishment, contract law is likely to regard
the patient as an autonomous party, ignoring the vulnerabilities of individuals
who are ill, dependent on the expertise of others, and may be desperate for therapeutic benefit.95
There is little regulation of online recruitment and that which does exist is
not focused on virtual clinical trials.96 The FDA has issued a guidance document
about the recruitment of clinical trial subjects through an advertisement which
“includes, but is not necessarily limited to: newspaper, radio, TV bulletin boards,
posters, and flyers that are intended for prospective subjects.”97 According to
the FDA guidance, advertising for clinical trial recruitment constitutes “the start
of the informed consent and subject selection process.”98 The FDA requires that
Institutional Review Boards review ads to ensure that they are not “unduly coercive and [do] not promise a certainty of cure beyond what is outlined in the consent and the protocol.”99 The FDA states that this requirement is particularly
important when research “may involve subjects who are likely to be vulnerable
MEDSCAPE (Mar. 1, 2012), http://www.medscape.com/viewarticle/759163 (explaining that while it is possible to form a physician-patient relationship online, it requires the physician to take an affirmative action
to be involved in the patient’s medical care).
93. See Moore, 793 P.2d at 484 (finding a legal cause of action for a person who had been subjected
to research without consent only because the participant had a physician-patient relationship with the researcher).
94. See Mytrus And Pfizer Win Best Practices Award For Pioneering Work In Electronic Consent
And Virtual Trials, MYTRUS (Feb. 10, 2014), https://www.mytrus.com/en/news/detail/20140211-scopeaward (awarding Mytrus and Pfizer, two private companies, for pioneering the clinical trial process); see
also Covington & Veley, supra note 22 (describing virtual clinical trials with technology platforms that
offer patient recruitment, consent, and data management, meaning the entire trial can be completed remotely via the internet); see also Covington & Veley, supra note 22 (describing virtual clinical trials with
technology platforms that offer patient recruitment, consent, and data management, meaning the entire
trial can be completed remotely via the internet); see also Grimes v. Kennedy Krieger Inst., Inc., 366 Md.
29 (2001) (finding that informed consent agreements in nontherapeutic research projects can constitute
contracts and create a special duty between participant and investigator).
95. Russell A. Hakes, Focusing On The Realities Of The Contracting Process—An Essential Step To
Achieve Justice In Contract Enforcement, 12 DEL. L. REV. 95, 100–01 (2011) (explaining that contract
theory assumes the freedom and autonomy of the actors when enforcing contracts, resulting in injustice
when reality does not match this assumption).
96. See Recruiting Study Subjects—Information Sheet: Guidance for Institutional Review Boards and
Clinical Investigators, FDA, http://www.fda.gov/RegulatoryInformation/Guidances/ucm126428.htm
(last updated Jan. 25, 2016) (stating that advertising for clinical trials online requires “no additional safeguard” but fails to mention the regulation of a virtual trial).
97. Id.
98. Id.
99. Id.
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to undue influence.”100 The guidance applies to online recruitment; however, it
also states that IRB review of advertisements over the internet is not necessary if
the advertisement displays limited information about the trial “such as the title;
purpose of the study; protocol summary; basic eligibility criteria; study site location(s) and how to contact the site for further information.”101
The problem with the FDA’s approach is that it focuses on what is presented
to the potential participant.102 As such, it pays no attention to how the potential
participant came to be targeted to begin with.103 In traditional medical research,
potential subjects were referred by their own physicians based on their actual
medical conditions.104 In virtual clinical trials, people who may be on the internet for wholly unrelated purposes are subjected to posts, banner ads, personal
emails, and other tactics asking them to participate in research.105 This new approach—targeting based on what a person does on the internet—raises several
problems.106 These include violation of privacy, exploitation of individuals who
are vulnerable (or more likely to be “good” trial participants in terms of adherence, not reporting adverse events, etc.) and coercion.107
The web is a target-rich area for finding research subjects because people
use the web in all aspects of their lives.108 They communicate with family members and friends, seek information, schedule appointments and trips, and reveal
personal, lifestyle, and medical information.109 Through their searches, purchases, and posts, people reveal information about their medical conditions.110
Health-related data can be analyzed from people’s general internet activities—
such as when they Google a particular ailment or medication, “like” a patients’
group such as a cancer society, or post unusual symptoms and request help from
friends to identify the cause of the disease or condition.111 Health-related data
100. Id.
101. Id.
102. Id. (directing the IRB to review materials).
103. Id.
104. Joseph Walker, Data Mining to Recruit Sick People, WALL ST. J. (Dec. 17, 2013),
http://www.wsj.com/articles/SB10001424052702303722104579240140554518458.
105. Id.
106. Id.; see also Brenda L. Curtis, Social Networking and Online Recruiting for HIV Research: Ethical Challenges, 9 J. EMPIRICAL RES. HUM. RES. ETHICS 58, 58, 66 (Feb. 20, 2014),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316828/pdf/nihms576496.pdf.
107. See infra note 218–219.
108. Alicia Shelton, A Reasonable Expectation of Privacy Online: “Do Not Track” Legislation, 45 U.
BALT. L.F. 35, 35, 38 (2014).
109. Id. LORI ANDREWS, I KNOW WHO YOU ARE AND I SAW WHAT YOU DID 2–3 (2012).
110. Shelton, supra note 108.
111. See Walker, supra note 104 (describing how health care companies are examining aggre-

gated data for clues about an individual’s health); see also Deborah Kogen, How Facebook Saved
My Son’s Life, SLATE (Jul. 13, 2011), www.slate.com/id/2297933 (describing a mother whose son
was diagnosed with a rare disease with the help of her friends after she posted her son’s symptoms
on Facebook).
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can also be gathered through medical and fitness apps (such as Fitbit)112 and
through digital games designed to help patients deal with certain diseases (such
as children with diabetes).113
When a person posts something related to health on a social networking
site, undertakes a web search for information about a particular disorder, or
emails a health professional through Gmail, data aggregators and medical researchers make assumptions about that person’s health and well-being.114 Medical researchers sometimes use data about people’s web searches, “likes,” and
health disclosures in private emails (such as over Gmail) to target potential research subjects.115
Online recruitment relies heavily on the collection and analysis of sensitive
health information and other personal information that people may not even realize they have revealed online. Clinical trial recruiters are using patient community sites, social networks, behavior-specific and disease-oriented sites, and
search engine queries about health behavior and medical conditions to identify
potential research subjects.116 But researchers are also using online data unrelated to health to make inferences about people’s health status and then recruit
them into studies. If a person subscribes to premium cable TV and eats in fastfood restaurants, he or she may be targeted for an obesity drug trial.117 According
to Roger Smith, Senior Vice President at the data aggregation company Acurian,
“We are now at a point where, based on your credit-card history, and whether
112. See FITBIT, FITBIT: CHARGEHR, http://www.fitbit.com/chargehr (the FitbitHR model of the fitness tracker tracks heart rate in addition to other health metrics); see also Stephen Armstrong, What Happens to Data Gathered by Health and Wellness Apps?, BMJ (2016), http://www.bmj.com/content/353/bmj.i3406 (reporting that much of the data tracked by health and fitness apps like Fitbit are sold
to third party companies).
113. See id. (reporting that much of the data tracked by health and fitness apps like Fitbit are sold to
third party companies); see also Sarah R. Blenner et al., Privacy Policies of Android Diabetes Apps and
Sharing of Health information, 315 JAMA 1051 (2016) (reporting the results of a study that found that
diabetes apps often collected and shared sensitive health information with third parties).
114. See Lauren Solberg, Regulating Human Subjects Research in the Information Age: Data Mining
on Social Networking Sites, 39 N. KY. L. REV. 327, 342–346 (2012) (stating that academic researchers are
data mining social networking sites for biomedical, social, and behavioral research); see also Julia
Angwin, The Web’s New Gold Mine: Your Secrets, WALL ST. J. (Jul. 30, 2010) http://online.wsj.com/article/SB10001424052748703940904575395073512989404.html (noting that website cookies and web
beacons – tiny snippets of tracking code– allow companies to scan an individual’s browsing patterns and
make assumptions about that individual’s income, shopping habits, and medical conditions); Google Privacy and Terms, GOOGLE, https://www.google.com/policies/terms/ (last visited Jan. 22, 2017) (stating
that Google scans the content of emails to provide tailored advertising and other relevant product features).
115. See Walker, supra note 104; see also E-Recruiting: Using Digital Platforms, Social Media, and
Mobile Technologies to Improve Clinical Trial Enrollment, supra note 8, at 10 (outlining how recruitment
companies can monitor social media sites and discussion boards to improve recruitment methods and
target potential participants); see also ANDREWS, supra note 109, at 45.
116. See E-Recruiting: Using Digital Platforms, Social Media, and Mobile Technologies to Improve
Clinical Trial Enrollment, supra note 8, at 10 (Oct. 14, 2003) (explaining that targeted advertisements on
digital platforms are a growing and effective way to recruit clinical trial participants).
117. Walker, supra note 104.
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you drive an American automobile and several other lifestyle factors, we can get
a very, very close bead on whether or not you have the disease state we’re looking at.”118 Ken Shore, the Executive Vice President of Blue Chip (another data
aggregation company like Acurian) explains that “[t]he types of magazines you
buy, how often you buy running shorts, all of those things tell a story.”119
When data aggregators obtain health data through online tracking mechanisms, individual privacy protections are limited to the dictates of company policies, which generally strip information divulged online of any privacy protections.120 While some data aggregators claim to protect sensitive personal
information, they adopt a definition of “sensitive” that fails to correspond to social expectations of privacy.121 Healthline Networks, Inc. places health-related
advertisements on sites such as Dr. Oz, AARP,122 Ask.com, and U.S. News123
based on the content of the page that the person is reading.124 Healthline claims
that it does not allow advertisers to track sensitive health information such as
HIV/AIDS, impotence, or eating disorders.125 However, it does permit tracking
of other potentially stigmatizing conditions such as anxiety and bipolar disorder.126
When data aggregators surreptitiously collect personal information about
online activity, they invade privacy and disregard the integral role that online
health resources play in today’s health care experience. Online health resources
may represent the only form of health care available to those who cannot afford
a doctor or otherwise lack access to professional medical help, are too embar-

118. Id.
119. Id.
120. See Sarah R. Blenner et al., supra note 113. (reporting the results of a study that found that diabetes apps often collected and shared sensitive health information with third parties).
121. See id. at 1053 (explaining that even apps with privacy policies commonly collect and share
sensitive information with third parties).
122. Wade Roush, Healthline Battles WebMD with Personalized Medical Search Tools, Body Maps,
XCONOMY (Nov. 30, 2011), http://www.xconomy.com/san-francisco/2011/11/30/healthline-battleswebmd-with-personalized-medical-search-tools-and-3d-body-maps/#.
123. Healthline Networks Takes in $21M Series B, VENTUREWIRE (July 17, 2007),
http://healthtools.aarp.org/corporate/news/Venture_Wire_HL_Networks_Takes_In_$21m.pdf
(noting
that Healthline secured distribution agreements to improve web site content for Aetna, AOL, Ask.com
and U.S. News and World Report).
124. See Angwin, supra note 114 (explaining that targeted advertising is growing to meet demand for
data on individual behavior and interests).
125. Id.
126. Id.
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rassed to seek in-person treatment, struggle daily with chronic illness, or are dissatisfied with past treatment results.127 Thus, many people view divulgence of
personal health information online as crucial to their personal welfare.128
The chronically ill are more likely than those who are healthy to search
online to learn more about medical conditions, such as depression or anxiety, as
well as drugs, insurance, and investigational treatments.129 Therefore, these people may have more data available for collection and are more likely to be solicited for clinical trials. According to a study by the Pew Research Center, the
chronically ill are more likely than other people to seek information online about
medical conditions, drugs and treatments, read drug and treatment reviews on the
internet and gather information on the internet about another person’s health situation.130 Sixty-two percent of internet users with two or more chronic illnesses
have looked online for information about a specific illness or problem.131 The
chronically ill, especially the homebound, tend to be more reliant on the internet
not only for health care information but also for social support.132
Some research and clinical trial recruitment services create websites that
provide medical information but may additionally or primarily exist to recruit
research participants. The clinical trial recruitment service MediGuard133 operates a website that offers to alert users about drug safety warnings and drug-drug
interactions and provides users with information about side effects, safety alerts,

127. See Daniel J. Amante, Access to Care and Use of the Internet to Search for Health Information:
Results From the US National Health Interview Survey, 17 J. MED. INTERNET RES. (2015),
https://www.jmir.org/article/viewFile/jmir_v17i4e106/2 (reporting that people who lack access to care for
various reasons are more likely to use the internet to search for health information); see also Magdalena
Berger et al., Internet Use and Stigmatized Illness, 61 SOC. SCI. & MED. 1821, 1826 (2005) (describing a
study that found that people with stigmatized illnesses are more likely to use the internet for health information that those with non-stigmatized illnesses); Susannah Fox & Kristen Purcell, Chronic Disease and
the Internet, PEW RES. CTR., 2 (Mar. 24, 2010), http://www.pewinternet.org/files/old-media//Files/Reports/2010/PIP_Chronic_Disease_with_topline.pdf (noting that “internet users living with chronic disease
are slightly more likely than other internet users to access health information online.”); Miriam McMullan,
Patients Using the Internet to Obtain Health Information, 63 PATIENT EDUC. & COUNSELING 24, 26
(2006) (describing a survey of cancer patients indicating that people who are dissatisfied with information
provided to them by health professionals often turn to the internet for information).
128. Amante, supra note 127. (finding that more than 40% of adults use the internet to search for
health information).
129. Fox & Purcell, supra note 127, at 2 and 17.
130. Susannah Fox & Maeve Duggan, Part One: Who Lives with Chronic Conditions, The Diagnosis
Difference, PEW RES. CTR., at 2 (Nov. 26, 2013), http://www.pewinternet.org/2013/11/26 /part-one-wholives-with-chronic-conditions/.
131. Susannah Fox & Maeve Duggan, Part Two: Sources of Health Information, PEW RES. CTR., at
14 (Nov. 26, 2013), http://www.pewinternet.org/2013/11/26/part-two-sources-of-health-information/.
132. Claire Cain Miller, Social Networks a Lifeline for the Chronically Ill, N.Y. TIMES, Mar. 25, 2010,
at B3.
133. Patient Recruitment, QUINTILES, http://www.quintiles.com/services/patient-recruitment (last accessed Nov. 2, 2016) (advertising patient recruitment services on digital patient communities such as
Mediguard.org).
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recalls and a pill reminder app for smartphones134—but only after individuals
provide information about their medical problems, drug allergies, medications,
age, sex, race, and email address.135 While the site appears to offer a public
service,136 MediGuard’s creator and CEO, Hugo Stephenson, says, “Our business is identifying patients for clinical research projects.”137 As of May 2016,
MediGuard had over 2.6 million members.138
Researchers also advertise on more traditional social networks such as Facebook because it is easy for the researcher to target subjects and for Facebook
users to share advertisements.139 Advertisements displayed on Facebook are
placed according to users’ membership in condition-related groups, forums, or
“likes,” and can be targeted according to gender, birthdate, and geographic location (as precise as a specific city radius or ZIP code).140 The Acurian Facebook
page, for example, shows an advertisement that reads: “Is asthma holding your
child back? Enroll now in research studies offering up to $1500.”141 The advertisement also gives Facebook users the option to “like” the ad, expanding its audience by sending the information to others in their friend networks.142 As Acurian notes, “because of the ‘viral’ character of social networks and activity,
message reach can expand exponentially—without exponential investment.”143
Social networks also allow recruiters to exploit social pressures to increase participation. Acurian encourages the use of social network site advertising because
“social networks provide the potential for—and advantage of—peer-to-peer influence and referral.”144 Targeted advertising on Facebook has already been used

134. MEDIGUARD, https://www.MediGuard.org (last visited Nov. 2, 2016); Press Release, QuintilesIMS, Patients Get Safety Information, Pill Reminders with New Mobile App from Quintiles, (Jan. 8,
2014),
http://www.quintiles.com/news/2014/01/patients-get-safety-information-pill-reminders-withnew-mobile-app-from-quintiles (announcing MediGuard’s new app that functions as a pill reminder).
135. Privacy Notice for Website, MEDIGUARD, https://www.mediguard.org/help/what-is-iguard/privacy (last updated Dec. 2013) (explaining that users must provide “‘sensitive’” information such as “race
and ethnicity, medicines, or health conditions of interest” to the site).
136. Allison, supra note 9, at 899; About Us, MEDIGUARD, https://www.mediguard.org/help/about_us
(last updated Nov. 1, 2013) (noting MediGuard is also known as iGuard).
137. Allison, supra note 9, at 899.
138. MEDIGUARD, https://www.mediguard.org/ (last visited Feb. 16, 2017).
139. Michael Kosinski et al., Facebook as a Research Tool for the Social Sciences, 70 AM.
PSYCHOLOGIST 543 (2015).
140. How to Target Facebook Ads, FACEBOOK BUS., https://www.facebook.com/business/a/onlinesales/ad-targeting-details (last visited Jan. 22, 2017).
141. AcurianHealth, FACEBOOK (Nov. 17, 2015), https://www.facebook.com/AcurianHealth/?fref=ts.
142. Id.
143. Scott Connor, Leveraging On-Line Social Networks for Clinical Trial Patient Recruitment,
ACURIAN WHITEPAPER SERIES, at 2 (2010), http://www.clinicalleader.com/doc/social-media-for-patientrecruitment-0001.
144. Id.
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to reach young women for a sexual desire study145 and to recruit teenagers for a
smoking cessation study.146
Federal regulators have not amended research guidelines to address internet
recruitment, even though internet recruitment creates unique risks.147 A person
may be harmed psychologically when a research recruiter calls or emails and
says, “Your Facebook profile indicates that you are at a high risk for an early
heart attack. Would you like to participate in a clinical trial to test a drug to avert
heart disease?” He may be harmed if he is aggressively targeted for participation
with promises of possible improvement and then denied admission to the trial
because of eligibility criteria without explanation or an offer of other support
services. He may be physically harmed by the experimental drug sent to his
home if the social media information or the Google searches do not actually reflect his health status. In addition, if a drug is approved for widespread use because of a faulty diagnosis, it may be ineffective or even harmful to people who
actually have the condition.
People have complained about unsolicited research recruitment, but such
complaints have not resulted in changes to the federal research regulations.148 A
website called Complaints Board features some people’s experiences with receiving unsolicited mail from Acurian.149 One person commented: “I agree with
complaint posted by person who received unsolicited mail from Acurian. I also

145. Deborah Borfitz, A Social Approach to Patient Recruitment, BIO-IT WORLD (May 18, 2010),
http://www.bio-itworld.com/BioIT_Article.aspx?id=98953.
146. Michelle A. Rait, et al., Recruitment of Adolescents for a Smoking Study: Use of Traditional
Strategies and Social Media, 5 TRANSL. BEHAV. MED. 254 (2015) (recruited teenage substance abusers
via social media).
147. See Covington & Veley, supra note 22 (commenting that there is little regulatory guidance for
conducting a virtual clinical trial); see also U.S. DEPT. HEALTH & HUMAN SERV., SEC’Y’S ADVISORY
COMM. ON HUMAN RESEARCH PROT., ATTACHMENT B: CONSIDERATIONS AND RECOMMENDATIONS
CONCERNING INTERNET RESEARCH AND HUMAN SUBJECTS RESEARCH REGULATIONS (2013) (discussing
how current human research regulations are outdated and do not address unique issues of internet research). FDA guidance for recruiting study subjects only references the internet to note that IRB review
and approval of listing of clinical trials on the internet is not required in most instances. See Recruiting
Study Subjects—Information Sheet Guidance for Institutional Review Boards and Clinical Investigators,
supra note 97. The U.S. Department of Health and Human Services, and fifteen other federal departments
announced proposed revisions to modernize the federal policy for protection of human subjects in September 2015. Federal Policy for the Protection of Human Subjects, 80 FR 53931 (proposed September 8,
2015). While the proposed rule addresses certain technological advances in human subject research, it
does not address online recruitment of human subjects. Id at 53936–37.
148. See Recruiting Study Subjects—Information Sheet Guidance for Institutional Review Boards and
Clinical Investigators, supra note 96 (explaining current regulations governing recruitment, which do not
specifically address online recruitment); see also E-Recruiting: Using Digital Platforms, Social Media,
and Mobile Technologies to Improve Clinical Trial Enrollment, supra note 8, at 10 (stating that there are
no regulations that govern what media may be used to recruit human subjects).
149. Comments Forum to Acurian, Inc: Unsolicited Mail, COMPLAINTS BOARD, http://www.complaintsboard.com/complaints/acurian-inc-pennsylvania-c574582.html (last updated Aug. 23, 2016).
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received a letter. Don’t have a clue as to where Acurian got my name and address. This can’t be legal. . . .”150 Another entry on the website reads: “My child
just received a letter asking her to participate in a clinical study, she’s a minor!
The only people who know of her disorder is her pediatrician and Walgreens
pharmacy!!! This can’t be legal!”151 Yet another comment states: “I worked in
clinical trials for over 10 years and agree that trials are very important. However,
my son (a minor) received the same letter. I have worked very hard safeguarding
his medical diagnosis. Outside of his doctor, pharmacy and school his name isn’t
attached or listed on anything.”152 Others complained about receiving an invitation from Acurian to participate in a clinical trial for a condition that they did not
have, but had only researched on the internet.153 In fact, Acurian was the cause
of over 500 Federal Trade Commission (“FTC”) complaints over a two-year period, and has been sued because of its telemarketing practices.154
Rather than expanding access to desperately needed experimental treatments, as expected by early advocates of online clinical trial listings and online
researchers, the internet may actually diminish opportunities for clinical trial participation.155 Targeted exclusively at individuals fitting a particular profile, clinical trial information will reach some eligible participants but not others.156 A
person’s social media profile is likely to contain inaccuracies, or have little bearing on medical eligibility, but it may nevertheless become the sole determinant
of whether an individual is selected for clinical trial participation.157 Able to
quickly and cheaply sort through thousands of potential clinical trial participants,
the clinical trial industry can now exploit narrow selection criteria.158 Instead of
contributing to the robustness of study design, online participant selection gives

150. L.N. Johnson, Comment to Acurian, Inc: Unsolicited Mail, COMPLAINTS BOARD (Jan. 5, 2012),
http://www.complaintsboard.com/complaints/acurian-inc-pennsylvania-c574582.html.
151. Montezumas Mom, Comment to Acurian, Inc; Unsolicited Mail, COMPLAINTS BOARD, (June 14,
2009), http://www.complaintsboard.com/complaints/acurian-inc-pennsylvania-c574582.html.
152. Keeping eyes open, Comment to Acurian, Inc; Unsolicited Mail, COMPLAINTS BOARD, (June 15,
2013), http://www.complaintsboard.com/complaints/acurian-inc-pennsylvania-c574582.html.
153. See, e.g., Walker, supra note 104.
154. See id. (explaining how the FTC alleges that Acurian violated standard telemarking laws; however, the commission has not made comments on the current investigation as a matter of policy).
155. See text infra at notes 156–159.
156. See, e.g., E-Recruiting: Using Digital Platforms, Social Media, and Mobile Technologies to improve Clinical Trial Enrollment, supra note 8 at 3, 8 (describing how e-recruiting on social media can
target niche patient groups precisely).
157. Erica Naone, When Social Media Mining Gets It Wrong, MIT TECH. REV. (Aug. 9, 2011),
https://www.technologyreview.com/s/424965/when-social-media-mining-gets-it-wrong/ (describing an
experiment in which data mining misidentified a person two thirds of the time and concluding that a Facebook profile is not a reliable source of information); see also Chetan Khatri et al., Social Media and
Internet Driven Study Recruitment, PLOS, at 2 (Mar. 16, 2015) (describing a study that evaluated the
effectiveness of recruiting solely through social media and concluded that it was cost effective).
158. See, e.g., Walker, supra note 104 (explaining online recruiting companies can sort through thousands of clinical trial participants and enroll larger numbers of patients in fast timeframes).
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researchers the opportunity and means to favor the efficient and successful completion of product testing.159 Will a segment of “optimal” participants—perhaps
characterized by a lack of assertiveness as to side effects, the absence of a support
system to oversee the process, or the lack of access to affordable alternatives—
define the future of clinical trials?
The online process for recruitment of clinical trial subjects not only threatens the privacy of people’s medical information but also lacks the transparency
that should be associated with medical or scientific research.160 Luring people
to a website which promises to provide a free service to help manage a person’s
condition when it instead exists primarily to collect and disclose people’s sensitive health information is dishonest and unethical.161 When people turn to the
online world to share medical information—for example, through social networks or patient support forums—they do so because they are seeking support
for a medical condition or concern.162 An online forum post is the virtual equivalent of a conversation in a physical support group, only more accessible.163 A
person may believe that a computer screen will protect his or her identity and the
privacy of his or her health information.164 Even if websites decide to engage in
greater transparency and tell users up front whether they disclose their personal
information to third parties, people should not have to decide between access to
information and attempting to safeguard their privacy.165
159. See Mark Zetin & Cara T. Hoepner, Relevance of Exclusion Criteria in Antidepressant Clinical
Trials, 27 J. CLINICAL PSYCHOPHARMACOLOGY 295, 300 (2007) (replicating and concurring with a study
that found that exclusion criteria in antidepressant trials is being used to find particular participants that
would produce ideal results for FDA marketing approval); see also, e.g., E-Recruiting: Using Digital
Platforms, Social Media, and Mobile Technologies to improve Clinical Trial Enrollment, supra note 8, at
3, 8 (advertising e-recruiting services capable of targeting precise groups of prospective subjects).
160. Allison, supra note 9, at 895, 899 (describing privacy concerns related to recruiting online and
noting that some companies appear to offer free services to help people manage their medication without
explaining that their business model is recruiting patients for clinical trials).
161. See id. at 899 (explaining how iGuard identifies patients for clinical research projects by offering
free tools to manage medications).
162. See, e.g., Jam Kotenko, The Doctor Will See You Now: How The Internet and Social Media Are
Changing Healthcare, DIGITAL TRENDS (Apr. 18, 2013), http://www.digitaltrends.com/social-media/theinternet-and-healthcare (noting how people use Twitter, Tumblr, and Facebook as virtual support groups);
see also Fox & Purcell, supra note 127 at 17, 20 (explaining how twenty-eight percent of internet users
living with disease use the internet to research their symptoms or talk to other users to inquire about their
experiences with the same disease).
163. Marsha White & Steve M. Dorman, Receiving Social Support Online: Implications for Health
Education, 16 HEALTH & EDUC. RES. 693, 694 (2001) (explaining how online support groups offer many
benefits like 24/7 access without having to leave home and anonymity).
164. See FTC Recommends Congress Require the Data Broker Industry to be More Transparent and
Give Consumers Greater Control over Their Personal Information, FTC (May 27, 2014),
https://www.ftc.gov/news-events/press-releases/2014/05/ftc-recommends-congress-require-data-brokerindustry-be-more (noting that many consumers are unaware that their data is being collected and sold).
165. See, e.g., INSTITUTE OF MEDICINE, HEALTH DATA IN THE INFORMATION AGE: USE, DISCLOSURE,
AND PRIVACY 17 (Molla S. Donaldson & Kathleen N. Lohr eds., 1994) (showing how consumers often
feel compelled to consent to waivers or they will forego the benefit sought and how those same consumers
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The vast amount of information that people knowingly, or sometimes inadvertently, reveal about themselves online creates benefits and risks in the health
research context.166 On the positive side, researchers can contact potential subjects directly, providing interested people with the opportunity to participate in
research.167 On the negative side, the information that study participants provide
online can be used by data aggregators in ways that disadvantage them.168 People
may be upset by the invasion of privacy and may suffer psychological harm.169
Moreover, the quality of the research may suffer due to this form of recruitment
if the targeted research subject looks for health information for someone else
online or if the researchers’ assumptions about the health status of consumers
based on their purchases are wrong (such as when someone who purchases premium cable is not obese).170
Targeted recruitment of clinical trial participants promises to increase
awareness of relevant trials while relieving researchers of some of the burden of
screening out the large percentage of interested individuals who are ultimately
deemed ineligible.171 However, online recruitment based on information acquired through non-transparent practices also threatens individual privacy rights,
the well-being of participants, the integrity of the trial process, and ultimately the
health of the public.

are not informed of how their records will be used in the future); see also Privacy Notice for Website,
supra note 135 (explaining how in order to receive services from MediGuard, customers must sign a
waiver that allows MediGuard to collect sensitive information).
166. See Walker, supra note 104 (explaining how health researchers can now find individuals who
would not show up through traditional profiling methods by using data information that they inadvertently
disclose, like online purchasing habits, or knowingly disclose, like their demographics).
167. Connor, supra note 143, at 1 (explaining how social media sites like Facebook and Snapchat
allow companies to place ads and trial information directly in front of potential subjects).
168. See, e.g., Walker, supra note 104 (explaining concerns that data may be used to deny employment
or reveal illnesses that people would like to keep private); see also Angwin, supra note 114 (noting that
there are no legal limits on how consumer data can be used).
169. See Michael McFarland, Why We Care about Privacy, MARKKULA CTR. FOR APPLIED ETHICS,
https://www.scu.edu/ethics/focus-areas/internet-ethics/resources/why-we-care-about-privacy/ (last accessed Jan. 22, 2017) (explaining how people can be harmed or disadvantaged if their personal information
becomes public).
170. See Walker, supra note 104 (explaining that Blue Chip Marketing found patients for an obesity
drug by targeting people who subscribe to premium cable and frequent fast food dining, characteristics
that suggest a sedentary lifestyle).
171. See Chetan Khatri et al., supra note 157, at 2 (noting that targeting on social media could reach
new pools of interests subjects and lead to more efficient recruitment); see also e-Recruiting: Using Digital Platforms, Social Media, and Mobile Technologies to Improve Clinical Trial Enrollment, supra note
8, at 2, 12 (describing targeted e-recruitment efforts which increased traffic to a trial website by about
6,500% and another that tripled the number of patient’s recruited while reducing recruitment costs).
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IV. EQUITABLE SELECTION IN RECRUITMENT
Although the federal research regulations do not comprehensively address
recruitment, they do require that the selection of subjects be “equitable.”172 This
means that even if the requirement of informed, voluntary participation in research is satisfied, doing research on a specific group of people if the research is
intended to benefit another group would violate the federal regulations.173 For
example, it would be inequitable to do research primarily on babies of color if a
particular condition affects babies of all races, especially if the parents of white
babies are more likely to afford treatments produced from such research. Equally
problematic is choosing a powerful group in society, such as men, and using
them as subjects in research for a condition that affects both men and women, if
the type of treatment developed will mainly benefit men.174 The federal research
regulations state that in order to ensure equitable selection, Institutional Review
Boards are required to consider the goals of the particular study, the setting in
which it will be conducted, and the special concerns raised by vulnerable research subjects such as children, prisoners and the disabled.175
In the process of drafting the federal research regulations, a government
commission analyzed the ethical concerns raised by research on humans in the
Belmont Report.176 The Report states that justice requires “researchers to exhibit
fairness: thus, they should not offer potentially beneficial research only to some
patients who are in their favor or select only ‘undesirable’ persons for risky research.”177 The Belmont Report also states that injustice in the recruitment of
172. 45 C.F.R. § 46.111(a)(3) (2015); 21 C.F.R. § 56.111 (a)(3) (2016).
173. See Equitable Selection of Participants, U. UTAH INSTITUTIONAL REV. BD., at 1,
http://irb.utah.edu/_pdf/BMGS-EquitableSelectionofParticipants.pdf (last visited Jan. 22, 2017) (requiring that benefits and burdens from research be distributed fairly); see also Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, 44 Fed. Reg. 23,192–93 (Apr.
18, 1979) [hereinafter Belmont Report] (explaining how the distribution of benefits and burdens should
be guided by the concept of justice).
174. See, e.g., Rebecca Dresser, Wanted Single, White Male for Medical Research, 22 HASTINGS CTR.
REP. 24, at 24, 27 (Feb. 1992) (noting how male-only studies of heart disease and cholesterol led the
American Heart Association to recommend a diet that could exacerbate the risk of heart disease among
women); Karen H. Rothenberg, Gender Matters: Implications for Clinical Research and Women’s Health
Care, 32 HOUS. L. REV. 1201, 1208 (1996) (describing how women were frequently left out of clinical
trials for AIDS therapies); R. Alta Charo, Protecting Us to Death: Women, Pregnancy, and Clinical Trials,
38 ST. LOUIS U. L.J. 135, 156 (1993) (stating that the exclusion of fertile women from research trials for
the sake of protecting the women and their future offspring ultimately leads the FDA to authorize marketing of untested drugs to such women).
175. See 45 C.F.R. § 46.111(a)(3) (2015); see also 21 C.F.R. § 56.111(a)(3) (2016).
176. See THE NAT’L COMM’N FOR THE PROT. OF HUM. SUBJECTS OF BIOMED. & BEHAV. RES., THE
BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR THE PROTECTION OF HUMAN SUBJECTS
OF RESEARCH (1979); see also Belmont Report, supra note 173, at 192–93 (Apr. 18, 1979) (providing a
summary of the 1979 Belmont Report and noting the abuses of human subjects in biomedical experiments
during World War II, which led to the Nuremberg code).
177. THE NAT’L COMM’N FOR THE PROT. OF HUM. SUBJECTS OF BIOMED. & BEHAV. RES., supra note
176, at 6-1, 6-2; Belmont Report, supra note 173, at 196.
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subjects may arise as a result of “social, racial, sexual and cultural biases institutionalized in society,” which may skew the distribution of risks and benefits of
research.178 Although the report clarifies that it is not the researchers’ duty to
correct institutionalized social injustices, it emphasizes that researchers can help
by “consider[ing] distributive justice in selecting research subjects,” thus minimizing the effect of social inequality.179
Another concern raised by inequitable selection is sampling bias.180 Sampling bias is an error introduced into the methodology of a particular research
initiative by recruiting subjects who are not truly representative of the population
that the sample is meant to study.181 As an example, a study to test the average
bone density of women between the ages of 35 to 40 that recruits only women
from a high-income urban neighborhood has a biased sample.182 Because
women living in a wealthy, city neighborhood are likely to have both better access to quality nutrition and more time to exercise than women of the same age
living in a low-income neighborhood or in a rural area, the sample of recruited
subjects is likely to skew the results of the study.183
Equitable selection of subjects is not adequately protected in virtual clinical
trials.184 At a basic level, the online platform is biased against people who are
poorer, older, and live in rural areas.185 Virtual clinical trials exclude those who
do not use the internet or those who do not own a computer or smartphone.186 If
178. Belmont Report, supra note 173, at 196.
179. See id. at 23,196–97; THE NAT’L COMM’N FOR THE PROT. OF HUM. SUBJECTS OF BIOMED. &
BEHAV. RES., supra note 176, at 6-1, 6-2.
180. See Dresser, supra note 174, at 26–27 (stating that injustice in the selection of human subjects
has contributed to imbalance in study populations).
181. See Elden Henson, A Pocket Guide to cGMP Sampling, INST. OF VALIDATION TECH., at 7–8
(2006),http://www.ivtnetwork.com/sites/default/files/A%20Pocket%20Guide%20to%20cGMP%20Sampling.pdf (providing the definition of sampling bias).
182. See Susan E. Parks et al., Differential Correlates of Physical Activity in Urban and Rural Adults
of Various Socioeconomic Backgrounds in the United States, 57 J. EPIDEMIOLOGY & CMTY. HEALTH 29,
34 (2003) (describing how lower income, rural residents were less likely than higher income, suburban
residents to meet physical activity recommendations).
183. See id.; see also Access to Healthy Foods in Low-Income Neighborhoods, RUDD CTR. FOR FOOD
POL’Y & OBESITY, 6 (2008), http://www.ct.gov/dph/lib/dph/hems/nutrition/pdf/yale_rudd_center_access_to_healthy_foods_report_2008.pdf (explaining that there are fewer supermarkets in low-income and
rural areas, which makes access to healthy and affordable foods more difficult than individuals who are
oppositely situated); Gina Shaw, Osteoporosis Tips: Build Stronger Bones, WEBMD (Jan. 14, 2011),
http://www.webmd.com/osteoporosis/features/build-stronger-bones?page=3 (explaining how nutrition
and exercise positively associate with greater bone density).
184. See Kathryn Zickuhr & Aaron Smith, Home Broadband 2013, PEW RES. CTR., 1, 3 (2013),
http://www.pewinternet.org/files/old-media/Files/Reports/2013/PIP_Broadband%202013_082613.pdf
(noting that only sixty-two percent of Americans living in rural areas, forty-three percent of those over
the age of sixty-five, thirty-seven percent of people who did not graduate from high school, and fifty-four
percent of those earning less than $30,000 per year have access to a fast internet connection).
185. Id.
186. See Kai Langel, Patient-Centric Engagement and the Digital Age, APPLIED CLINICAL TRIALS
(Apr. 1, 2014), http://www.appliedclinicaltrialsonline.com/patient-centric-engagement-and-digital-age
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the studies require extensive data collection through a computer, this may be
more difficult for people with a slow internet connection. Furthermore, if the
study is limited to individuals using a more expensive smartphone (such as an
iPhone), the research would only involve wealthier individuals.187 Currently, all
three of these problems exist.
A 2014 poll conducted by the Pew Research Center found that 13 percent
of adults in America do not use the internet.188 Another study also conducted by
the Pew Research Center found that although the use of the internet and ownership of computers is prevalent in U.S. households, there are still disparities in the
way internet connectivity is distributed across different geographic areas.189 The
study found that, for example, in the Boulder metropolitan area approximately
eight out of ten homes had access to a fast, broadband internet connection
whereas in other metropolitan areas such as Harlingen, Texas, only approximately half of the homes have access to a fast internet connection.190 In general,
approximately 30 percent of the U.S. population does not have access to a fast
internet connection at home.191 The most affected groups include those who did
not graduate from high school, people over the age of 65, those earning less than
$30,000 per year, and those living in rural communities.192
Inequitable internet access means that although computer use and internet
access is prevalent in the U.S., some populations may not be easily accessible for
recruitment or for participation in online medical research.193 If people in specific geographic areas are significantly less likely to turn to the internet for medical information because they have no access to a fast internet connection, researchers recruiting subjects based on their online searches would be less likely

(noting how there is some bias in virtual clinical trials due to individuals who lack Internet access being
unable to participate).
187. See Zickuhr & Smith, supra note 184, at 2, 6 (finding those with high income and educational
attainment are much more likely to own iPhones).
188. See Susannah Fox & Lee Rainie, The Web at 25 in the U.S., PEW RES. CTR., 5 (Feb. 27, 2014),
http://www.pewinternet.org/files/2014/02/PIP_25th-anniversary-of-the-Web_0227141.pdf (stating 87
percent of adults use the internet).
189. Lee Rainie & D’Vera Cohn, Census: Computer Ownership, Internet Connection Varies Widely
Across U.S., PEW RES CTR, (Sept. 19, 2014), http://www.pewresearch.org/fact-tank/2014/09/19/censuscomputer-ownership-internet-connection-varies-widely-across-u-s/.
190. Id.
191. See Zickuhr & Smith, supra note 184, at 2 (Aug. 26, 2013), http://www.pewinternet.org/~/media//Files/Reports/2013/PIP_Broadband%202013_082613.pdf (finding 70 percent of the U.S. population
has access to a high speed internet connection at home).
192. See id. at 3 (finding 62 percent of Americans living in rural areas, 43 percent of those over the
age of 65, 37 percent of people who did not graduate from high school, and 54 percent pf those earning
less than $30,000 per year have access to a fast internet connection).
193. See Amneris E. Luque et al., Barriers and Facilitators of Online Patient Portals to Personal
Health Records Among Persons Living with HIV, 2 JMIR RES. PROTOCOL. 1, 6 (2013) (finding that inadequate internet access made access to online medical research more difficult.).

2018]

VIRTUAL CLINICAL TRIALS

215

to recruit these people for studies. Because historically disadvantaged populations often lack a fast internet connection, recruitment of subjects for clinical
research that relies exclusively on an online framework would be inherently inequitable.
For example, in online clinical research trials such as Pfizer’s REMOTE or
Ivivi’s EMF trial, there were issues of equitable selection of subjects because the
trials required subjects to have access to an internet connection.194 In online
clinical trials, subjects complete informed consent forms online and constantly
enter information on the trial’s website.195 For Ivivi’s Osteoarthritis EMF study
it can take up to 20 minutes for the subjects to complete the required data forms
online.196 Since the entire trial depends upon constant and reliable access to fast
internet, the recruitment and enrollment of subjects for these trials would be inherently inequitable, disproportionately excluding disadvantaged populations
such as the elderly or low-income earners.
If a potential subject is required to have a high-end smartphone to participate, only wealthier individuals will have access to the clinical trials. A 2013
Pew Research Center poll revealed that 91 percent of adults own a cellphone197
and 56 percent of cellphone users own a smartphone.198 Generally, research conducted using smartphones presents problems of equitable subject selection.199
People over the age of 65, people who did not graduate from high school, and
those with an income lower than $30,000 per year are less likely to own a
smartphone than the rest of the population.200
Using the iPhone’s ResearchKit as the platform for virtual clinical trials
presents even greater issues of equitable subject selection and sampling bias due
to the difference in the demographics of people who use Apple’s iPhone instead
of smartphones with other operating systems. ResearchKit is an “open-source
framework” which allows researchers to create medical apps to conduct research
on iPhone users exclusively.201 By utilizing the iPhone’s internal instruments,
194. See Orri et. al., supra note 28, at 191 (stating that REMOTE trial participants were enrolled and
managed entirely remotely through internet and mobile-phone platforms); see also Amp Orthopedics, supra note 23 (listing daily access to the internet as one of the inclusion criteria).
195. Orri et al., supra note 28, at 191.
196. Mytrus Ivivi Osteoarthritis Study, supra note 70.
197. Lee Rainie, Cell Phone Ownership Hits 91% of Adults, PEW RES. CTR. (June 6, 2013),
http://www.pewresearch.org/fact-tank/2013/06/06/cell-phone-ownership-hits-91-of-adults/.
198. Aaron Smith, Smartphone Ownership 2013; 56% of American Adults Are Now Smartphone Owners,” PEW RES. CTR. (June 5, 2013), http://www.pewinternet.org/2013/06/05/smartphone-ownership2013/, at 2.
199. Id., at 3 (describing a study that found that only about half of Americans are smartphone owners
and those who own smartphones tend to be educated and wealthy).
200. Id. at 3–4.
201. See ResearchKit and CareKit, APPLE, https://www.apple.com/researchkit/ (last visited Jan. 22,
2017); see also ResearchKit for Developers, APPLE, https://developer.apple.com/researchkit/ (last visited
Jan. 22, 2017).
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such as the phone’s accelerometer and gyroscope, and by using the information
collected from HealthKit—a set of apps which allow the user to enter health information and which also collect data passively—researchers can conduct studies on subjects remotely and collect metrics at any time of the day.202 Current
ResearchKit initiatives include medical research studies on asthma, Parkinson’s
disease, and diabetes.203
The future of ResearchKit may also involve virtual clinical trials for pharmaceutical companies. In July 2015, GlaxoSmithKline announced that it was in
the planning phases of using ResearchKit for drug research and development.204
The pharmaceutical company behind the painkiller OxyContin, Purdue Pharma,
also told reporters that it was exploring the possibility of using ResearchKit for
drug research and development.205 Apple’s Senior Vice President of Operations
said that the company would be open to for-profit efforts that are going to “make
an impact on people’s health” and that this is the reason why Apple made ResearchKit an open-source platform.206
According to a Pew Research Center poll conducted in 2013, 40 percent of
people earning over $75,000 a year own an iPhone compared to only 13 percent
of those who earn less than $30,000 per year.207 Also, while 38 percent of college
graduate smartphone users own an iPhone, only 11 percent of smartphone users
who did not graduate high school own one.208 The disparity in iPhone ownership
is even greater in the African-American community, in which only 16 percent of
smartphone users own an iPhone.209
By conducting medical research exclusively on a narrow segment of the
population, ResearchKit—and virtual clinical trials in general—presents issues
of equitable selection as well as sampling bias. The risks and benefits of research
will not be distributed across a representative sample of the general population
or even the general smartphone-owning population. For example, people who
202. ResearchKit and CareKit, supra note 201; see also HealthKit, APPLE, https://developer.apple.com/healthkit/ (last visited Jan. 22, 2017) (stating that customers may provide permission for the app
to passively collect data to be used in research).
203. ResearchKit and CareKit, supra note 201.
204. See Stephanie M. Lee, Big Pharma Eyes iPhone for Drug R&D, BUZZFEEDNEWS (last updated
July 12, 2015, 1:31 PM), http://www.buzzfeed.com/stephaniemlee/big-pharma-eyes-apples-researchkitfor-drug-development#.hfOa1GEnq; see also GSK, TWITTER (July 10, 2015, 1:56 PM) https://twitter.com/GSK/status/619565807325048832; Can an iPhone Transform the Way we Monitor and Improve
Patient Health?, GSK (July 8, 2016), http://us.gsk.com/en-us/behind-the-science/innovation/can-an-iphone-transform-the-way-we-monitor-and-improve-patient-health/.
205. See Lee, supra note 204 (“Purdue Pharma, the privately held, multibillion-dollar drug developer
in Connecticut that’s best known for OxyContin painkillers, told BuzzFeed News that it’s in the early
stages of exploring whether Apple’s new tool for research data collection can be used as part of its own
drug R&D efforts.”).
206. Id.
207. Smith, supra note 198, at 7.
208. Id.
209. Id.
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choose to participate in ResearchKit studies are not only likely to be representative of the average iPhone user demographic (high-income, college-educated individuals) but also include those who use the iPhone’s HealthKit to keep track
of their calorie intake or step count.210 Any developments that result from the
research—such as a new drug—will have been developed from a very narrow
sample of people; as commentators point out, a section of the “richest 15 percent
of the world”211 that is proactive about managing their conditions and improving
their health.212
At the same time, however, virtual clinical trials can test the most dangerous
treatments on low-income and disadvantaged populations. Researchers in the
past have recruited vulnerable subjects and performed risky research on them.213
For example, research sites have recruited homeless people214 and undocumented
immigrants215 to participate in drug trials. These participants enter the trial for
the opportunity to earn desperately needed money.216 Researchers have failed to
ensure that a participant is not simultaneously participating in several trials,
which can affect the results of the studies.217 Virtual clinical trials create even
more opportunities to target vulnerable populations. Online behavioral marketing studies have demonstrated how to identify vulnerable, easy-to-manipulate

210. Id. (finding that more than three times as many iPhone users made over $75,000 per year, compared to iPhone users who made less than $30,000 per year; and more than three times as many iPhone
users were college-educated than did not graduate high-school); see also ResearchKit, APPLE, http://researchkit.org/ (last visited Jan. 22, 2017) (“ResearchKit works seamlessly with HealthKit, researchers can
access even more relevant data for their studies—like daily step counts, calorie use, and heart rate.”).
211. See Jim Edwards, The iPhone 6 Had Better Be Amazing and Cheap, Because Apple Is Losing the
War to Android, BUS. INSIDER (May 31, 2014, 8:27 AM), http://www.businessinsider.com/iphone-v-android-market-share-2014-5 (explaining that the high price of Apple smartphones may be limiting its market share to 15%).
212. See Arielle Duhaime-Ross, Apple’s New ResearchKit, THE VERGE (Mar. 10, 2015),
http://www.theverge.com/2015/3/10/8177683/apple-research-kit-app-ethics-medical-research (explaining that people who use ResearchKit are more likely to be engaged in monitoring and improving their
health, and may not represent the entire population affected by the disease).
213. Susan Perry, Recruitment of Homeless People for Drug Trials Raises Serious Ethical Issues, U
Bioethicist Says, MINNPOST, (Aug. 11, 2014), https://www.minnpost.com/second-opinion/2014/08/recruitment-homeless-people-drug-trials-raises-serious-ethical-issues-u-bioet; see also, Carl Elliott, The
Best-Selling, Billion-Dollar Pills Tested on Homeless People; How the Destitute and the Mentally Ill Are
Being Used as Human Lab Rats, MATTER (July 28, 2014), https://medium.com/matter/did-big-pharmatest-your-meds-on-homeless-people-a6d8d3fc7dfe#.eoz7mpmb2; David Evans, Michael Smith & Liz
Willen, Big Pharma’s Shameful Secret, BLOOMBERG MKT, (Special Report, Dec. 2005), http://www.journalism.columbia.edu/system/documents/523/original/2006_Evans_Big_Pharma_s_Shameful_Secret_MAG.pdf.
214. See Elliot, supra note 213 (stating that research organizations send employees to homeless shelters to recruit patients).
215. See Evans et al., supra note 213, at 37–38, 42 (quoting an undocumented immigrant who volunteered as a patient to earn desperately-needed money for his family).
216. See id. at 37 (noting that patients who are desperate for money will participate in trials specifically
for the monetary compensation).
217. Id. at 39.
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people.218 Data aggregators actually sell email lists labeled “sucker lists” of gullible people.219
As pharmaceutical companies harvest increasingly rich sources of consumer and patient data, they are likely to adjust their product development priorities.220 The profiles generated from online and offline data may reveal relationships between particular conditions and optimal consumer populations—those
who are wealthier, more likely to adhere to brand-name drugs, more likely to
influence prescribing practices, or more likely to accept stigmatized diagnoses.221 In addition, extensive behavioral data available about people based on
their activities across the web can enable researchers to identify and recruit subjects who typically do not complain, thus leading to approval of a drug that has
undocumented side effects. The development of treatments based on inequitable
recruitment in virtual clinical trials may thus undermine the social goal of developing safe and effective treatments for the entire population.
V. INFORMED CONSENT
Informed consent is an essential prerequisite to medical research.222 People
cannot be required to be guinea pigs. A basic human right exists to refuse to
participate in research for whatever reason.223 In fact, the first principle of the

218. Nathan Newman, How Big Data Enables Economic Harm to Consumers, Especially to LowIncome and Other Vulnerable Sectors of the Population, 18 J. INTERNET L. 11, 14 (2014).
219. Id. at 14.
220. Jamie Cattell, et al., How Big Data Can Revolutionize Pharmaceutical R&D, MCKINSEY &
COMPANY (Apr. 2013), http://www.mckinsey.com/industries/pharmaceuticals-and- medical-products/our-insights/how- big-data- can-revolutionize- pharmaceutical-r- and-d.
221. Id. (explaining that pharmaceutical companies can use data mining to identify new potential drugs
and focus R&D resources on drugs that are likely to be successful). Researchers might themselves choose
only the wealthiest subjects by using data from their choice of websites (such as high end shopping sites)
or their use of expensive digital devices. This allows the recruitment of subjects who will be able to afford
expensive treatments. The pricing of the resulting treatment might prevent others from having access to
the benefits of the research.
222. NUERNBERG MILITARY TRIBUNALS VOL. II, supra note 29, at 181–182.
223. See generally World Medical Association, Declaration of Helsinki–Ethical Principles for Medical Research Involving Human Subjects, 5, http://www.wma.net/en/30publications/10policies/b3/index.html.pdf?print-media-type&footer-right=[page]/[toPage] (last amended Oct. 2013) (explaining that
all subjects must be notified of their right to refuse to participate in a study).
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Nuremberg Code, the international standard for medical research, is that participation must be informed and voluntary.224 Similar provisions exist in U.S. federal research regulations, which apply to all federally-funded research225 and to
research that will be used in efforts to obtain Food and Drug Administration approval for a drug or other product.226 The federal regulations, influenced by the
Nuremberg Code, have extensive requirements regarding what must be disclosed
to potential research subjects and what must be done to ensure that a person is
not coerced into participating in research.227 The regulations also require that
informed consent forms include a “statement that participation is voluntary.”228
The subject’s right to be informed about the risks and benefits of the proposed
research before they are enrolled in a research study and the right to refuse to
participate in research is also part of medical ethics codes229 and common law
legal obligations.230 For certain vulnerable groups—such as children—additional protections are in place under the federal research regulations.231 Because

224. See NUERNBERG MILITARY TRIBUNALS VOL. II, supra note 29, at 181–82. The first tenet of the
Nuremberg Code is: “1. The voluntary consent of the human subject is absolutely essential. This means
that the person involved should have legal capacity to give consent; should be so situated as to be able to
exercise free power of choice, without the intervention of any element of force, fraud, deceit, duress, overreaching, or other ulterior form of constraint or coercion; and should have sufficient knowledge and comprehension of the elements of the subject matter involved, as to enable him to make an understanding and
enlightened decision. This latter element requires that, before the acceptance of an affirmative decision by
the experimental subject, there should be made known to him the nature, duration, and purpose of the
experiment; the method and means by which it is to be conducted; all inconveniences and hazards reasonably to be expected; and the effects upon his health or person, which may possibly come from his participation in the experiment.” Id.
225. See 45 C.F.R. § 46.122 (2009) (“Federal funds administered by a department or agency may not
be expended for research involving human subjects unless the requirements of this policy have been satisfied.”); see also 45 C.F.R. § 46.116 (2009) (listing the general requirements for informed consent).
226. See 21 C.F.R. § 50.25 (2015) (explaining that informed consent includes a statement noting participation is voluntary); see also 21 C.F.R. § 50.1 (2015) (“Compliance with these parts is intended to
protect the rights and safety of subjects involved.”).
227. See 21 C.F.R. § 50.20 (2015) (noting that research shall not be undertaken without informed
consent and the representative must have a chance to consider whether to participate or not); see also 21
C.F.R. § 50 (2015) (instructing people to lie because they have gotten the evidence paper as well as assigned her extra); 21 C.F.R. § 25 (2015) (explaining that informed consent includes a statement noting
participation is voluntary); 45 C.F.R. § 46.111(a)(4) (2009) (“Informed consent will be sought from each
prospective subject.”); 46 C.F.R. § 46.116 (2009) (explaining that investigators must receive informed
consent from the subject).
228. See 21 C.F.R. § 50.25(a)(8) (2015) (noting that participants must receive a statement that participation is voluntary); see also 45 C.F.R. § 46.116(a)(8) (2009) (explaining that investigators must receive
informed consent from the subject).
229. The AMA Code of Medical Ethics’ Opinion on Clinical Research, 17 AM. MED. ASS’N J. ETHICS
1136, 1136–37 (Dec. 2015).
230. See Moore v. Regents of the Univ. of Cal., 793 P.2d 479, 483 (1990) (explaining that physicians
who fail to disclose research or commercial motives will create a cause of action for performing a medical
procedure without the patient’s informed consent).
231. See 45 C.F.R. §§ 46.404–46.409 (2015) (specifying categories of research that are not suitable
for children and the requirements for proper assent by children to participate in a study); see also 21 C.F.R.
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of concerns that children cannot meet the requirements of voluntary informed
consent,232 certain risky research on children is prohibited altogether.233
Consent collected online—often referred to as electronic consent or e-consent—does not adequately guarantee that the consent is informed or voluntary,
which is problematic both for the individual and for ensuring the validity of the
research.234 With online consent, the person signing the consent form may not
be the person he or she claims to be.235 A reporter was able to lie about her age
in one of the ResearchKit apps in order to qualify for a study.236 The team behind
the Parkinson’s ResearchKit app deliberately chose to allow the system to give
a person more than one opportunity to become eligible for the study: “It’s tough,
you know—it’s certainly possible to have a system where you only get one shot
with the eligibility criteria in our studies; but we chose not to do that.”237
Little is done to verify the identity of research subjects.238 One group of
online medical researchers suggests that it may be prudent to require a photo ID
to verify the age and identity of potential subjects.239 This might be possible
using the same scanning technology that banks use for mobile check deposits,240
as well as the widely available barcode scanning technology for smartphones.241
However, a teenager pretending to be an adult could easily scan a parent’s ID to
§§ 50.52–50.54 (2016) (specifying what types of research are permissible by the Food and Drug Administration when children are the subjects in clinical investigations).
232. See, e.g., Teresa Hughes & Mary Kay Helling, A Case for Obtaining Informed Consent From
Young Children, 6 EARLY CHILDHOOD RES. Q. 225, 227 (1991) (“Children’s limited experiences and
developmental level make it difficult for them to understand long-term goals of research, the concept of
risk, and the meaning of self-determination.”).
233. See 45 C.F.R. §§ 46.404–46.409 (specifying categories of research that are not suitable for children and the requirements for proper assent by children to participate in a study); see also 21 C.F.R. §§
50.51–50.56.
234. See text accompanying infra at notes 235–257.
235. See Duhaime-Ross, supra note 212 (one reporter changed her age on ResearchKit to become
eligible for a research study, illustrating the issue of minors being able to participate in research despite
being unable to legally consent).
236. Id.
237. Id.
238. See Considerations and Recommendations Concerning Internet Research and Human Subjects
Research Regulations, with Revisions, THE SEC’Y’S ADVISORY COMM. ON HUMAN RES. PROTS., HEALTH
& HUMAN SERVS, at 14 (2013) (explaining that “identity verification is a major issue in Internet research.”); see also id. (describing an online study where she was able to return to the previous page and
change her age in order to become eligible).
239. See Duhaime-Ross, supra note 212.
240. See Jeffrey Kopchik, Supervisory Insights, FED. DEPOSIT INS. CORP., https://www.fdic.gov/regulations/examinations/supervisory/insights/sisum09/primer.html (last updated June 29, 2009) (explaining
“remote deposit capture” technology in which users take a photo of the check, electronically submitting it
to the bank, quickly adding credit to the user’s bank account).
241. See Jesse Emspak, Smartphone App Foils Would-Be Underage Drinkers, MASHABLE, (July 11,
2013), http://mashable.com/2013/07/11/barzapp-app-underage-drinkers/#CpmP8ISsGkqy (describing a
new smartphone app, BarZapp, which scans the barcode on the back of an ID and instantly verifies the
age of a person).
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meet the criteria. Furthermore, requiring participants to provide additional personal data increases the risk of identity theft.242
The online consent process also eliminates the role of an intermediary capable of evaluating patient capacity and voluntariness, which are requisite for
informed consent.243 Can a software program adequately detect impairments in
the functional abilities involved in subject comprehension of information and use
of information to evaluate the desirability of the balance between the study’s
risks and potential benefits? Can software detect extreme influences on the patient’s indicated preferences, such as overwhelming family pressure to participate in the study for the possible therapeutic benefit, compensated care, or even
payments for participation?
Furthermore, by removing the informed consent process from an in-person
setting, online research eliminates a crucial aspect of the process, which is the
dialogue between a potential subject and an investigator.244 Is there sufficient
dialogue and interaction to make the informed consent process meaningful when
the subject is simply tapping through e-consent prompts on a tablet screen?245
Making the informed consent process entirely digital hinders opportunity for
such dialogue to take place.246 In a virtual clinical trial, without in-person physician oversight, a participant’s additional conditions or use of drugs may go unnoticed, and lead to increased risks during the experimental treatment.247

242. See, e.g., Lorenzo Franceschi-Bicchierai, Uber Left Hundreds of Drivers’ Licenses and Social
Security Numbers Exposed, MOTHERBOARD (Oct. 13, 2015, 6:52 PM), http://motherboard.vice.com/read/uber-left-hundreds-of-drivers-licenses-and-social-security-numbers-exposed?111
(describing a data breach of Uber that exposed hundreds of drivers’ licenses, tax forms, and social security
numbers); see also Ted Samson, Flaw in Popular Mobile Apps Exposes Users to Identity Theft,
INFOWORLD (Apr. 9, 2012), http://www.infoworld.com/article/2617115/mobile-security/flaw-in-popular-mobile-apps-exposes-users-to-identity-theft.html (describing a flaw in popular mobile apps such as
Facebook, Dropbox, and LinkedIn, which exposed users to identity theft “by saving user authentication
keys in easily accessible, unencrypted plain text files.”).
243. See Umesh Chandra Gupta, Informed Consent in Clinical Research: Revisiting Few Concepts
and Areas, 4 PERSP. IN CLINICAL RES. 26, 26–27, 29 (2013) (explaining that the three essential elements
of informed consent are “voluntarism, information disclosure, and decision-making capacity”; researchers
are responsible for ensuring patients are participating voluntarily, provided with information relevant to
making an informed decision, and able to understand and appreciate the decision they are making).
244. See Duhaime-Ross, supra note 212 (“Despite some improvements to the informed consent process, one problem remains: many of these apps haven’t figured out a way to let users ask a question during
the process, which is what the one-on-one interaction allows.”); see also INST. OF MED. OF THE NAT’L
ACADS., RESPONSIBLE RESEARCH: A SYSTEMS APPROACH TO PROTECTING RESEARCH PARTICIPANTS
120–23 (Daniel D. Federman et al. eds., 2003) (recommending that informed consent should consist of an
“ongoing, interactive dialogue between research staff and research participants”).
245. See Christine Coughlin, E-Consent: Can Informed Consent be Just a Click Away?, 50 WAKE
FOREST L. REV. 381, 394–95 (2015), at 394 (explaining that subjects are far less likely to read consent
forms “on a screen or a tablet versus a hard copy”).
246. Duhaime-Ross, supra note 212; see also supra text accompanying note 243.
247. See Coughlin, supra note 245, at 395 (explaining that reducing in-person interactions “increases
the likelihood that physicians would not recognize shifting patient vulnerabilities.”).
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To the extent that the companies have made the electronic consent forms
available, it appears that the forms allow the participants’ information to be used
beyond the initial study in studies the person has not specifically consented to.248
This conflicts with the principle that people should be informed about the particular nature and risk of a study that they are being asked to participate in. It also
runs afoul of the clear evidence, from studies249 and cases,250 that research subjects have strong feelings about the types of research they want to participate in.
People’s consent to one type of research does not imply consent to another type
of research.251 If information voluntarily provided for one study is used without

248. See Marianne Kolbasuk McGee, Apple’s ResearchKit: The Privacy Issues, DATA BREACH
TODAY (Mar. 16, 2015), http://www.databreachtoday.com/apples-researchkit-privacy-issues-a-8018 (explaining that although Apple’s ResearchKit provides informed consent to consumers prior to participating
in clinical studies through an app, “[i]t’s not clear how ResearchKit and end users determine which apps
have access to what data, for what purposes, and for how long.” Furthermore, once an entity has a consumer’s personal information “there is no way to know what they do with it . . . It is also relatively easy
for a “malicious developer” to create an app and divulge private information.). See Valerie Gutmann
Koch, PGTandMe: Social Networking-Based Genetic Testing and the Evolving Research Model, 22, 51
HEALTH MATRIX 33 (2012) (noting that using a person’s information in “studies that were not identified
at the time of enrollment challenges current expectations of how research protocols are defined and what
it means to participate in research.”). The strength of research subjects’ desire to determine what type of
research is performed on their information or samples is evinced by the fact that research subjects have
sued research institutions that have used their samples for studies beyond the initial consented-to research.
See, e.g., Havasupai Tribe of Havasupai Reservation v. Ariz. Bd. of Regents, 204 P.3d 1063 (Ariz. Ct.
App. 2008).
249. See M.L. Goodson & B.G. Vernon, A Study of Public Opinion on the Use of Tissue Samples from
Living Subjects for Clinical Research, 57 J. CLINICAL PATHOLOGY 135, 136–37 (2004) (asserting that
many participants seek control over their tissues and will only join types of research that allows that control); see also Åsa Kettis-Lindblad et al., Perceptions of Potential Donors in the Swedish Public Towards
Information and Consent Procedures in Relation to Use of Human Tissue Samples in Biobanks: A Population-Based Study, 35 SCANDINAVIAN J. PUB. HEALTH 148, 155 (2007) (suggesting that research procedures should be specialized based on the preferences of the participant); Briana Mezuk et al., Participant
Characteristics That Influence Consent for Genetic Research in a Population-Based Survey: The Baltimore Epidemiologic Catchment Area Follow-up, 11 COMMUNITY GENETICS 171, 173–76 (2008) (stating
that their study shows that people are influenced into participating by many variables); Jeanette M. Trauth
et al., Public Attitudes Regarding Willingness to Participate in Medical Research Studies, 12 J. HEALTH
& SOC. POL’Y 23, 39–40 (2000) (focusing on what life experiences influence people the most to participate
in certain research studies); Lori B. Andrews and Julie Burger Chronis, A Pound of Flesh: Patient Legal
Action for Human Research Protections in the Biotech Age, in PATIENTS AS POLICY ACTORS 83 (2011);
Lori B. Andrews, Assessing Values to Set Policies for Consent, Storage, and Use of Tissue and Information in Biobanks, in NEW CHALLENGES FOR BIOBANKS: ETHICS, LAW AND GOVERNANCE 31 (2009).
250. See Washington Univ. v. Catalona, 490 F.3d 667, 673 (8th Cir. 2006) (allowing research participants to intervene and attempt to direct the transfer of their biological samples); see also Havasupai Tribe
v. Ariz. Bd. of Regents, 204 P.3d 1063 (Ariz. Ct. App. 2008) (tribe whose blood was collected for diabetes
research objected to its use in other studies).
251. See Greenberg v. Miami Children’s Hosp. Research Inst. Inc., 208 F.Supp.2d 918, 921–22 (N.D.
Ill. 2002) (involving participants who sued a research hospital and researcher when their biological samples were used to file for a patent rather than provide support on an affordable and accessible basis).
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specific consent for a different study, the nature of the latter study may be objectionable to the participant.252 The participant may have been drawn to the initial
research because it focused on a disease that affected his or her family and may
not wish to participate in other research.253 Also, the trust that the subjects have
in the initial researcher may not carry over to unspecified future researchers.254
There is reason to suspect that the risks of participation are not adequately
explained in a digital informed consent form.255 It is unlikely that such forms
include disclosure of the risks of stigmatization or discrimination associated with
the aggregation of data about an individual.256 The informed consent form may
even fail to adequately disclose the risks of the drug being used in the research.257
Some of the research studies undertaken via virtual clinical trials involve
drugs which have been approved by the FDA to treat one condition being used
for another condition.258 Miguel Orri, then Senior Director at Pfizer said that in
the original REMOTE trial, researchers used “an approved drug, with a wellestablished safety profile in a condition where patients don’t die” (emphasis

252. See Goodson & Vernon, supra note 249, at 136–37 (saying that many participants want some
type of control over their tissues and want to be consulted when their tissues are used for a different study);
see also Kettis-Lindblad et al., supra note 249, at 154–55 (suggesting that there should be informed consent every time there is a different study than was originally entered into); see also Marc D. Schwartz et
al., Consent to the Use of Stored DNA for Genetics Research: A Survey of Attitudes in the Jewish Population, 98 AM. J. MED. Genetics 336-341 (2001) (noting that people want researchers to get their informed
consent each time their tissues are used for different research).
253. See Trauth et al., supra note 249, at 31–40 (finding that those with sick family members and
friends were significantly more willing to participate in medical research trials).
254. See Havasupai Tribe v. Ariz. Bd. of Regents, 204 P.3d 1063 (Ariz. Ct. App. 2008) (explaining
that the Havasupai Tribe agreed to participate in a study focused on diabetes after a researcher developed
a strong relationship with the tribe, then sued when they found out that their blood samples were used for
projects that were not related to diabetes).
255. See Coughlin, supra note 245, at 382, 393–95.
256. See Eric T. Juengst, Human Genetics ‘98: Ethical Issues In Genetics, Group Identity and Human
Diversity, 63 AM. J. HUM. GENETICS 673, 673, 677 (1998) (explaining that research that finds a genetic
propensity for alcoholism in a particular group could be misinterpreted and applied to all members of a
the group in a discriminatory way and arguing that individuals should be informed of this risk); see also
Schwartz et al., supra note 252, at 336, 341 (surveying Jewish individuals and finding that they were less
willing to participate in research regarding stereotypical or potentially stigmatizing traits).
257. See I. N. Olver et al., The Adequacy of Consent Forms for Informing Patients Entering Oncological Clinical Trials, 6 ANNALS OF ONCOLOGY 867, 867–69 (1995) (discussing how many participants
could not name the severe side-effects of drugs even after reading the consent form).
258. See Jean Fain, A Miracle Drug For Binge Eating? Not So Fast, Says Therapist, WBUR (Feb. 10,
2015),
http://www.wbur.org/commonhealth/2015/02/10/a-miracle-drug-for-binge-eating-not-so-fastsays-therapist (the use of Vyvanse for binge eating disorder would have severe side-effects for the user,
even though it has been approved for another condition).
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added).259 Yet, just because a drug has been approved for a particular condition
does not mean it is 100% safe or that it will be safe for another condition.260
Virtual clinical trials are used to study new uses of old drugs.261 Pharmaceutical companies are rebranding some of their top-selling drugs and marketing
them for a different condition either because the patent is running out or simply
because they want to expand the market for the drugs.262 The researcher undertaking a virtual clinical trial with a previously-approved drug might be tempted
to say in the informed consent form that the drug is “safe” based on previous
approval. But the researcher may be failing to take into consideration the risks
and benefits of the drug in a different circumstance.263 While the risks of a drug
259. See Kai Langel, Virtual Clinical Trials –”They’re Here to Stay”, ECLINICALHEALTH BLOG (Mar.
18, 2013), https://www.clinpal.com/clinpal-blog/virtual-clinical-trials-theyre-here-to-stay/.
260. See Fain, supra note 258. The author explains that although the drug Vyvanse has been used to
treat ADHD there may be numerous drawbacks to the use of the drug for the treatment of binge eating
disorder. Id.
261. See Langel, supra note 259 (explaining that the regulators were likely more willing to approve
the REMOTE virtual trial because the drug was already FDA approved).
262. See Mary Ebeling, Beyond Advertising: The Pharmaceutical Industry’s Hidden Marketing Tactics, PRWATCH (Feb. 21, 2008, 12:00 PM), http://www.prwatch.org/news/2008/02/7026/beyond-advertising-pharmaceutical-industrys-hidden-marketing-tactics (explaining that Eli Lilly rebranded Prozac,
used to treat depression, as Sarafem, used to treat premenstrual dysphoric disorder, effectively extending
the patent on Prozac); see also John Russell, Humira: One Drug. Nine Uses. More on the Way?, CHI.
TRIB. (Sept. 18, 2015), http://www.chicagotribune.com/business/ct-humira-swiss-army-knife-0920-biz20150918-story.html (stating that pharmaceutical companies are trying to repurpose old drugs in order to
gain money by skipping phase one of clinical trials).
263. For example, Sarafem has the same exact chemical composition as Prozac, but Sarafem is intended for the treatment of premenstrual dysphoric disorder instead of depression. See Ebeling, supra note
262. (describing the severe side-effects of Prozac and why it may not be a good idea to use it for other
conditions). Another example is a drug called Vyvanse—made by the pharmaceutical company Shire—
which was originally used to treat attention deficit hyperactivity disorder (ADHD) but that is now being
used to treat binge eating disorder because “there was no other drug treatment available for the disorder.”
See Katie Thomas, Shire, Maker of Binge-Eating Drug Vyvanse, First Marketed the Disease, N.Y. TIMES
(Feb. 24, 2015), http://www.nytimes.com/2015/02/25/business/shire-maker-of-binge-eating-drugvyvanse-first-marketed-the-disease.html?_r=1 (stating that Vyvanse was approved without a committee
because there was no other drugs available for binge-eating disorder). The FDA did not request review by
an advisory committee because the drug’s “safety profile is well known.” Id. According to the Physician’s
Desk Reference website “anaphylaxis/angioedema requiring hospitalization and emergency treatment occurred with 1st or subsequent doses” of Tolterodine tartrate (the drug used for the REMOTE trial). See
Tolterodine Tartrate—Drug Summary, PDR.NET, http://www.pdr.net/drug-summary/detrol-la?druglabelid=477 (last visited Jan. 22, 2017) (describing the effects and warnings of the drug Detrol.); see also
Stuart Henochowicz, Anaphylaxis, MEDLINEPLUS (Mar. 20, 2016). Similarly, Sarafem contains a boxed
warning of an increased risk of suicide as well as extensive warnings including possible allergic reactions,
bleeding, hyponatremia and the potential to “precipitate mixed/manic episode in patients at risk for bipolar
disorder.” See Fluoxetine Hydrochloride—Drug Summary, PDR.NET, http://www.pdr.net/drug-summary/Sarafem-Tablets-fluoxetine-hydrochloride-1946.5777 (last visited Jan. 22, 2017) (summarizing the
drugs warnings and why it might not be smart to use for different conditions); see also Drug Advertising:
A Glossary of Terms—Boxed Warning, FDA, http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/ucm072025.htm (last updated June 19, 2015) (explaining the function of
a black box warning for drugs). Also, according to the Physicians’ Desk Reference, as a stimulant,
Vyvanse has a “high potential for abuse and dependence” and may produce anxiety, anorexia, increased
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might be tolerable when applied to a particular disease, such as one that is particularly devastating or that has no other treatment, that does not mean there
would be an identical risk calculus for another disease.264
The FDA authorized the REMOTE trial because it had been designed to
test the feasibility and methodology of conducting clinical trials online,265 and
the FDA wanted to determine how the informed consent process would work
when done entirely online.266 Mytrus’ electronic informed consent (“eConsent”)
system is called Enroll.267 Enroll provides the informed consent form and an
accompanying video in a digital interactive format through an iPad.268 The process includes different interactive features and questionnaires to assess the comprehension of the participant.269 According to Mytrus, this system will make the
clinical trial process more cost effective.270 A report indicates that most of the
ten biggest pharmaceutical companies are using Mytrus’ Enroll electronic consent system,271 and according to Mytrus’ website, 30 IRBs have approved use of
its Enroll system.272 Other electronic informed consent forms exist, such as one

heart rate, sudden death and stroke. See Lisdexamfetamine Dimesylate—Drug Summary, PDR.NET,
http://www.pdr.net/drug-summary/vyvanse?druglabelid=538 (last visited Jan. 22, 2017) (explaining the
warnings of using Vyvanse and suggesting why it might not be smart to use for other conditions).
264. See Guidance for Industry: Expedited Programs for Serious Conditions—Drugs and Biologics,
U.S. DEPT. HEALTH & HUM. SERV. (May 2014), http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf (stating that the FDA is willing to accept greater
risks and side effects from treatment for serious diseases and therefore some trials should receive accelerated approval); see also Understanding Unapproved Use of Approved Drugs “Off Label”, U. S. DEPT.
HEALTH. & HUM. SERV. (May 2017), https://www.fda.gov/forpatients/other/offlabel/default.htm (advising patients considering off label use of FDA approved drugs to weigh the risks and benefits).
265. See Pfizer Conducts First “Virtual” Clinical Trial Allowing Patients to Participate Regardless
of Geography, PFIZER (June 7, 2011), http://press.pfizer.com/press-release/pfizer-conducts-first-virtualclinical-trial-allowing-patients-participate-regardless- (stating that the goal of the virtual trial was to test
this method compared to an on-site clinical trial).
266. See Mike Mitka, Strategies Sought for Reducing Cost, Improving Efficiency of Clinical Research,
306 JAMA 364, 365 (2011).
267. Reinvent Consent with Enroll, MYTRUS, https://www.mytrus.com/en/products-services/enroll
(last visited Jan. 22, 2017).
268. See id. (denoting the Enroll app’s operation through an iPad).
269. See id. (discussing the features Enroll uses to enhance a clinical trial participant’s understanding).
270. See Kristen Schneider, Mytrus Pioneers to Patient-Friendly Technologies for Clinical Trials Participation, SARTA (May 9, 2014), http://sarta.org/blog/mytrus-pioneers-to-patient-friendly-technologiesfor-clinical-trials-participation/ (addressing the increased cost efficiency of the Enroll system).
271. Id.
272. Reinvent Consent With Enroll, supra note 267.
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designed by Sage Bionetworks that uses icons and explanations273 and one designed by surgeons at the Medical College of Wisconsin.274
Enroll allows subjects to flag terms they do not understand and click
through to obtain more information, and in some cases even call a person.275 The
system also collects data regarding how long a patient looked at each screen of
the electronic informed consent form on the iPad and regarding sections where a
participant had trouble understanding a particular idea or word.276 However, this
system cannot determine if the subjects’ consent is either informed or voluntary.277 The system is not designed to eliminate someone who reads the informed
consent disclaimer in just a few seconds or who genuinely does not understand
certain aspects of the study.278 Furthermore, the eConsent model does not address the difficulty in ascertaining whether the person signing the eConsent form
in an entirely online clinical trial is actually the subject participating in the research study.279
The FDA notes that although use of the electronic informed consent may
make research easier for sponsors, they “must attend to privacy and confidenti-

273. See John Wilbanks & Erin Holve, EDM Forum’s Collaborative Network, PCOR, and Apple’s
Research Kit, ACADAMYHEALTH (Apr. 14, 2015), http://www.academyhealth.org/blog/2015-04/edm-forums-collaborative-network-pcor-and-apples-research-kit (discussing the two tiers of Sage Bionetworks
system, the first tier being “icon dominant” and the second tier being more text and detail dominant).
274. See Matthew J. Frelich et. al., Research Electronic Data Capture (REDCap) Electronic Informed
Consent Form (eICF) is Compliant and Feasible in a Clinical Research Setting, 2 INT’L J. CLINICAL
TRIALS 51, 52 (2015) (addressing the creation of an electronic informed consent by Vanderbilt University
with partners such as the Medical College of Wisconsin).
275. See Ann Neuer, Informed Consent Goes Digital, CLINICAL INFORMATICS NEWS (Aug. 29, 2013),
http://www.clinicalinformaticsnews.com/cln/2013/8/29/informed-consent-goes-digital.html (explaining
that the subject has the option to select “I understand,” or “I have a question” before getting to the next
screen; if the subject selects the question option, a site staff then reviews the information with the subject
and answers any questions).
276. Id.
277. See NUERNBERG MILITARY TRIBUNALS VOL. II, supra note 29, 181–182 (discussing the high
standard for consent to be both informed and voluntary and allowing inference that the standard would be
difficult to meet through Mytrus’s electronic Enroll system).
278. See Reinvent Consent With Enroll, supra note 267 (noting Enroll’s capabilities, which do not
include the ability to screen out participants who read the informed consent too quickly or who are genuinely confused about a study).
279. See Reinvent Consent With Enroll, supra note 267 (highlighting Enroll’s capabilities, which do
not address imposters in clinical trials); see also Duhaime-Ross, supra note 212 (discussing the risk of
imposters and false claims of identity in clinical trials).
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ality concerns when considering techniques for monitoring informed consent remotely.”280 Although the FDA’s main concern seem to be the accuracy and quality of the data obtained from the trial,281 equally important is the vulnerability of
access to private health information. Data breaches involving protected health
information have increased exponentially.282 As a result of the expected expansion in the use of electronic health records and cloud storage services, data
breaches of health information are expected to increase.283
Informed consent is a crucial component of research on human subjects
because protection of an individual’s autonomy to make decisions for himself or
herself is not only legally required, but widely recognized as a fundamental principle of medical ethics.284 The informed consent methodology used in virtual
clinical trials does not adequately protect research participants.
VI. CONFIDENTIALITY AND PRIVACY
The disclosure of health information is a sensitive matter. The quality of
health care is based primarily on information that physicians get directly from
their patients.285 If patients withhold information from their physicians, it may
lead to ineffective care or even to potentially unnecessary procedures leading to

280. See U.S. Dep’t Health & Hum. Serv. et al., Guidance of Industry: Oversight for Clinical Investigations—A Risk-Based Approach to Monitoring, FDA GUIDANCE DOCUMENTS (Aug. 2013), at 9,
http://www.fda.gov/downloads/Drugs/. . ./Guidances/UCM269919.pdf.
281. See id. at 1, 11 (explaining that the “nonbinding recommendations” provided by the FDA center
around ensuring that a site’s records are complete, that the information regarding subjects be accurate, and
that there is a low frequency of protocol violations).
282. See Vincent Liu et al., Data Breaches of Protected Health Information in the United States, 313
JAMA 1471, 1472 (2014). A study in the April 14, 2015 JAMA issue reported that “between 2010 and
2013, breaches of protected health information reported by HIPAA-covered entities increased and involved approximately 29 million records, with most data breaches resulting from overt criminal activity.”
The study focused on a U.S. Department of Health and Human Services database which listed “data
breaches of unencrypted protected health information.” The authors noted that most of such breaches
(67%) occurred through the use of electronics—such as computers. They further noted that due to the fact
that they used data pertaining to reported breaches only “[their] study likely underestimated the true number of health care data breaches occurring each year.”
283. See id. (predicting that data breaches are likely to increase because of increased use of “cloud
based services provided by vendors supporting predictive analytics, personal health records, health-related
sensors, and gene sequencing technology”).
284. 21 C.F.R. § 50.20 (2016); 45 C.F.R. § 46.116; THE NAT’L COMM’N FOR THE PROT. OF HUM.
SUBJECTS OF BIOMED. AND BEHAV. RESEARCH, supra note 176, at 10.
285. See, e.g., Kevin McCarthy, Study: 50 Percent of Patients Withhold Information from their Doctor, NUEMD (Sept. 21, 2016), http://www.nuemd.com/news/2014/12/19/study-50-percent-patients-withhold-information-their-doctor (“Patients who withhold information about their medication use are increasing their chances of experiencing an adverse drug event, and individuals who lie about their diet or activity
level may be withholding valuable diagnostic clues.”).
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higher health care costs.286 Therefore, it is vital to ensure that an individual’s
health information remains private so that patients are willing to answer sensitive
questions honestly.287 Furthermore, unwanted disclosures of private health information may lead to discrimination, stigmatization, embarrassment, denial of
services and benefits, as well as other serious adverse consequences.288
Various federal laws have been adopted to protect health information specifically, such as the privacy regulations289 adopted under the Health Insurance
Portability and Accountability Act290 and the federal research regulations, which
state that Institutional Review Boards must determine whether a research plan
contains adequate safeguards to protect the subjects’ privacy and confidentiality
prior to approving a study.291 Some states have also enacted measures to protect
people’s health information.292
However, many of the federal and state legal protections fail to protect medical information online. For example, the privacy regulations293 adopted under
HIPAA294 only apply to specifically-defined “covered entities,” which include
health care providers and plans, but not internet sites where researchers conduct
online medical research. State laws are also limited in the type of health information that they protect295; for example, Rhode Island’s law related to the privacy and confidentiality of medical information prohibits “any person” from disclosing a patient’s “confidential health care information” without the patient’s

286. See, e.g., Sally E. Thorne et al., Is There a Cost to Poor Communication in Cancer Care?: A
Critical Review of the Literature, 14 PSYCHO-ONCOLOGY 875, 879–80 (2005) (reviewing empirical literature of communication between cancer patients and their doctors and finding that poor communication
leads to higher healthcare costs).
287. See Katherine M. Woods & Regis McNamara, Confidentiality: Its Effect on Interviewee Behavior, 11 PROF. PSYCHOL. 714, 719 (1980) (describing a study in which interviewees who were told their
answers might not be confidential disclosed less information).
288. INST. OF MED, BEYOND THE HIPAA PRIVACY RULE: ENHANCING PRIVACY, IMPROVING HEALTH
THROUGH RESEARCH 77 (Sharyl J. Nass et al. eds., 2009).
289. The HIPAA Privacy Rule, 45 C.F.R. § 160 (2016); 45 C.F.R. § 164.102–106 (2016); 45 C.F.R.
§ 164.500–534 (2016).
290. The Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191, 100 Stat.
1936 (codified as amended in scattered sections of 26, 42 U.S.C.).
291. See 45 C.F.R. § 46.111(a)(7) (2015) (“In order to approve research covered by this policy the
IRB shall determine that [among other things] . . . [w]hen appropriate, there are adequate provisions to
protect the privacy of subjects and to maintain the confidentiality of data.”).
292. See, e.g., R.I. GEN. LAWS § 5-37.3-4 (2016) (requiring written consent of the patient prior to the
release or transfer of confidential health care information); see also CAL. CIV. CODE § 56.06 (a), (b) (West
2016) (requiring that businesses that offer software or hardware for maintaining medical information be
held to the same standards of confidentiality as health care providers).
293. See 45 C.F.R. § 160.103 (2015) (defining covered entities as a health plan, a health clearing
house, or a health care provider who transmits health information electronically).
294. The Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104-191, 100 Stat.
1936 (codified as amended in scattered sections of 26, 42 U.S.C.).
295. 45 C.F.R. § 160.103 (2015).
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consent.296 This law, however, only protects confidential health care information
related to “health care history, diagnosis, condition treatment or evaluation obtained from a health care provider who has treated the patient.”297 Such narrow
protections ignore the high risks associated with the collection of exactly the
same types of information by different entities merely because those entities are
not involved with treating the patient.
Some states have begun to express concern about health care information
disclosure online. California and Delaware, for example, require that websites
that collect personally identifiable information post a privacy policy about the
type of information they collect. 298 An additional California law requires that
“any business that offers software or hardware to consumers” with the purpose
of allowing consumers to “maintain medical information” or for “the diagnosis,
treatment, or management of a medical condition” be considered as “a provider
of healthcare” for purposes of requiring such entity to maintain “the same standards of confidentiality required of a provider of health care with respect to medical information disclosed to the business.” 299 This means that disclosures of
health information by such medical apps or websites for the purpose of recruitment would be considered actionable as a breach of confidentiality. In addition,
unauthorized disclosure of health information to marketers or third parties that
was collected during the study through the app designed to monitor health would
be actionable.300
Researchers who conduct virtual clinical trials may inadvertently violate
their subjects’ privacy. This can happen in a variety of ways—from accessing
and combining private data to determine who should be recruited into a study,301
to passively collecting data without consent (such as measuring a person’s speech
pattern through an app’s use of a phone’s microphone302 or the person’s gait

296. R.I. GEN. LAWS § 5-37.3-4 (a)(1)–(2) (2016).
297. R.I. GEN. LAWS § 5-37.3-3 (3)(ii) (2016).
298. CAL. BUS & PROF. CODE § 22575 (a), (b)(1) (West 2013); DEL. CODE ANN. 6, § 1205C (a), (b)(1)
(2016).
299. CAL. CIV. CODE § 56.06(a)–(c) (West 2009).
300. See CAL. CIV. CODE §56.36 (b)(1)–(2) (West 2007) (providing penalties for the violation of the
confidentiality provision in the form of a private cause of action); see also, CAL. CIV. CODE § 56.36 (a),
(c) (West 2007) (providing for further penalties in the form of criminal charges and administrative fines).
301. See, e.g., Walker, supra note 104 (highlighting how an individual may have been targeted for an
arthritis clinical trial based off of innocuous web-browsing and/or credit card spending).
302. See, e.g., Zoe Kleinman, Is Your Smartphone Listening to You?, BBC (Mar. 2, 2016),
http://www.bbc.com/news/technology-35639549 (highlighting how an android-platform based mobilephone application can be easily created to listen in on conversations in the presence of the device that the
application is installed in).
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when a phone is in the person’s pocket),303 to storing research data with inadequate cyberprotection,304 to aggregating data in a way that puts subjects at risk
of disclosure of private facts leading to stigmatization and discrimination.305
Virtual clinical trial researchers have created a market for privacy violations, incentivizing data aggregators’ collection of data in much the same way
they originally created the market that encouraged physicians to enroll their own
patients in clinical trials. Commentators criticized this earlier system because it
incentivized physicians to behave in unscrupulous ways in order to get large
sums of money from pharmaceutical companies in exchange for enrolling their
patients.306 Now, researchers are encouraging data aggregators to invade people’s privacy through the surreptitious collection of data, thereby creating this
new market.307 Because the HIPAA Privacy Rule does not cover online medical
data that is not in the control of health care institutions or health care providers,
entities that sell consumers’ private data to researchers can violate people’s privacy in their attempt to identify research subjects.308 Data can be legally collected about people’s private web searches, social media posts and even their
private email messages to friends, and can be used to recruit subjects based on
inferred characteristics.309 Theses technically legal practices that researchers use
303. See, e.g., Apple Announces New ResearchKit Studies for Autism, Epilepsy & Melanoma, APPLE
(Oct. 15, 2015), http://www.apple.com/pr/library/2015/10/15Apple-Announces-New-ResearchKit-Studies-for-Autism-Epilepsy-Melanoma.html; see also ResearchKit and CareKit; Empowering Medical Researchers, Doctors, and Now You, APPLE, http://www.apple.com/researchkit/ (last visited Jan. 22, 2017)
(discussing how the “mPower” app is helping researchers understand Parkinson’s disease by using iPhone
features to measure, along-side of other features, gait).
304. See, e.g., Improper Disclosure of Research Participants’ Protected Health Information Results
in $3.9 Million HIPAA Settlement, U.S DEPT. HEALTH & HUM. SERV. (Mar. 17, 2016),
http://www.hhs.gov/about/news/2016/03/17/improper-disclosure-research-participants-protected-healthinformation-results-in-hipaa-settlement.html (detailing how the Feinstein Institute for Medical Research
was fined for, among other things, storing research data without appropriate cyber-protection which led
to a breach of that data).
305. See Leslie Wolf et al., Certificates of Confidentiality: Protecting Human Subject Research Data
in Law and Practice, 14 MINN. J.L. SCI. & TECH. 11, 16–17 (2013) (demonstrating how research data
collected may be exposed through litigation, exposing participants to stigmatization).
306. See generally Trudo Lemmens & Paul B. Miller, The Human Subjects Trade: Ethical and Legal
Issues Surrounding Recruitment Incentives, 31 J.L. MED. & ETHICS 398, 401 (2003) (discussing how “financial pressures may bring physicians to stretch the inclusion and exclusion criteria [of a clinical trial
testing a new medication] to enroll as many patients as they can, thereby compromising the trial’s validity”).
307. See generally Sorrell v. IMS Health Inc., 564 U.S. 552 (2011) (health data miners prevailed in a
First Amendment challenge to a Vermont statute that protected the privacy of information about doctors’
prescribing patterns); also see generally Erika Check Hayden, Mobile-Phone Health Apps Deliver Data
Bounty, 531 NATURE 422 (2016), http://www.nature.com/news/mobile-phone-health-apps-deliver-databounty-1.19622 (noting that researchers are realizing the value of collecting health data through apps and
the scope of such programs is expanding).
308. See generally Nicholas P. Terry, Big Data Proxies and Health Privacy Exceptionalism, 24
HEALTH MATRIX: J.L.-MED. 65, 84–87 (2015) (describing “medically infected data,” data that although
is not strictly medical, can be collected to infer medical status yet fall outside the scope of HIPPA’s reach).
309. Walker, supra note 104.
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to collect people’s data are nonetheless particularly intrusive and violate people’s
privacy.310
Targeted advertisements to recruit clinical trial participants also raise privacy concerns.311 For example, if a person Googles a disease, a clinical trial ad
can appear related to that disease312 on another Google service. Imagine watching a YouTube video with your child when an advertisement appears asking you
to participate in a clinical trial about cancer or sexually-transmitted diseases because you have searched for information about the condition online.
Once researchers identify a potential subject, new privacy risks arise. Virtual clinical trials collect data online, often through medical apps.313 However,
computers and cell phones are riddled with surreptitious tracking mechanisms
such as cookies.314 Medical and clinical trial apps are sometimes designed to
send private health information to data aggregators.315 A study conducted at IIT
Chicago-Kent College of Law about diabetes apps found that over 80% of the
apps sent user health information to third-party data aggregators.316
The virtual clinical trial model also presents unique privacy issues because
of the nature of digital information and storage. Because the information for
such trials is stored and transmitted exclusively online through computers or mobile devices, any party besides the subject of an online clinical trial can potentially gain access to the information by using the device without the subject’s
authorization.317 Since trial information—including informed consent forms and

310. Terry, supra note 308 at 84–85 (providing examples of where data are collected including “webbrowsing trails, exhaust data from online transactions, web scrapers, social media interactions, mobile
phone usage, smartphone sensors, mobile health apps, and both medical and non-medical networked devices”).
311. See, e.g., Brenda L. Curtis, Social Networking and Online Recruiting for HIV Research: Ethical
Challenges,
9
J.
EMPIRICAL
RES.
HUM.
RES.
ETHICS
58,
59–60
(2014),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316828/pdf/nihms576496.pdf (describing privacy issues associated with targeted online recruiting for HIV research).
312. See Privacy Policy, GOOGLE, https://www.google.com/policies/privacy/#nosharing (last visited
Jan. 22, 2017).
313. Maged N. Kamel Boulos et al., Mobile Medical and Health Apps: State of the Art, Concerns,
Regulatory Control and Certification, 5 ONLINE J. PUB. HEALTH INFORMATICS 1, 4 (2014) (describing
trials that use mobile apps to collect health information such as body weight, calorie loss and diseasesymptoms).
314. See Jonathan R. Mayer & John C. Mitchell, Third Party Web Tracking: Policy and Technology,
CTR. FOR INTERNET & SOC’Y (2012), https://jonathanmayer.org/papers_data/trackingsurvey12.pdf (discussing methods of tracking mechanisms such as “cookies”).
315. See Sarah R. Blenner et al., supra note 113 (finding that a majority of diabetes apps surveyed use
tracking cookies to collect user information, and many shared their information with third party data aggregators).
316. Id.
317. Cf. Kesa Bond et al., Electronic Health Records: Privacy, Confidentiality, and Security, 14
VIRTUAL MENTOR 712, 714 (2012), http://journalofethics.ama-assn.org/2012/09/stas1-1209.html (noting
that physicians with unencrypted mobile devices leave digitally transmitted information vulnerable to interception).
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subjects’ health information—are stored online for clinical trials such as Pfizer’s
REMOTE, there is the additional risk that a data breach can expose people’s
sensitive medical data.318
Some commentators argue that collecting information from websites and
social media does not constitute an invasion of privacy because such sources are
generally considered public places.319 However, privacy scholars have argued
in various contexts that privacy extends to otherwise public places when people
have a reasonable expectation of privacy about the acts happening in the public
setting.320 Should it be considered a violation of privacy to use a sound amplifier
to listen to two people’s conversation in a café? How about recording such a
conversation without their consent? The fact that the internet may be a “public
place” for some does not mean that traditionally private information put on the
internet should lose its private nature, especially if it is private health information, which has historically been considered amongst the most private information about a person.
In addition, much of the data collected by data aggregators comes from
online sources that the users themselves view as private—email, password-protected websites and so forth.321 When people realize that data aggregators are
collecting extensive information about them, many want legal change. A 2016
Pew Research Center study asked participants whether they would join a free
social media website to communicate with old acquaintances about a class reunion if the website collected information about them to show them targeted advertisements.322 Most of the participants said they would not find that scenario acceptable.323 Similarly, a Gallup poll found that 67 percent of adult Americans
opposed being targeted by behavioral advertising and believe that advertisers

318. See, e.g., James Paul et al., The Internet and Clinical Trials: Background, Online Resources,
Examples and Issues, J. MED. INTERNET RES. (2005), http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550630/?report=printable (asserting that security is a “central issue” when housing trial information online, as well as describing ways in which that security can be breached); see also Orri et al.,
supra note 28 at 193–97 (noting that, in a virtual clinical trial, all the study data collected was transferred
to an electronic database).
319. See Solberg, supra note 114 (explaining that courts have found no reasonable expectation of
privacy in posts on a social media site).
320. See, e.g., Carlos A. Ball, Privacy, Property, and Public Sex, 18 COLUM. J. GENDER & L. 1, 33
(2008) (arguing that the 4th Amendment protections of individuals beyond private residences allows for
a sexual act occurring in public to take on a private dimension by the nature of the act itself).
321. Cf. Blenner et al., supra note 113, at 1051 (finding that a large percentage of diabetes apps, with
a presumption of privacy, were sold to third party data aggregators).
322. See Lee Rainie & Maeve Duggan, Privacy and Information Sharing, PEW RES. CENT., at 31–32
(Jan. 14, 2016), http://www.pewinternet.org/2016/01/14/privacy-and-information-sharing/ (finding that,
while many Americans are willing to disclose information for a tangible benefit, they are cautious about
doing so and are often unsatisfied when they know what a company will do with it).
323. Id. at 32.
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should not be allowed to match advertisements to their particular interests according to the websites they have visited.324 The same poll found that 61 percent
of Americans believe that the use of targeted advertisements is not justified even
if reduces costs because free access to websites is not worth the invasion of privacy involved.325 A 2012 Pew poll found that 73 percent of Americans interviewed said they would not be okay with a search engine keeping track of their
online searches and subsequently using this information to personalize search
results in the future because it is an invasion of privacy, and 68 percent of participants in the same poll said “they are not okay with targeted advertisements
because they do not like having their online behavior tracked and analyzed.”326
A breach of privacy in the virtual clinical trial context can exacerbate psychological harms evidenced in other online contexts.327 A teenager who searches
for a size 14 prom dress or looks up a diet online may be emotionally devastated
if the subsequent sites that she visits advertise weight loss trials for overweight
teenagers. The target of an online advertisement might also face a physical risk,
if she is lured into an inappropriate clinical trial and subsequently takes medication when she does not have the target condition. She may also face a risk if she
avoids medical care due to the quick fix the “novel” therapy offered through
participation in a research trial. Or she may lose the chance to benefit from an
online support group if she withdraws due to privacy concerns after her name
has “leaked” to recruiters.
Surreptitious data collection from social networks for medical research may
also interfere with patients’ use of the web to gain information or learn from
other patients.328 A triumph of social networks has been the way people isolated

324. See Lymari Morales, U.S. Internet Users Ready to Limit Online Tracking for Ads, GALLUP (Dec.
21, 2010), http://www.gallup.com/poll/145337/Internet-Users-Ready-Limit-Online-Tracking-Ads.aspx.
325. Id.
326. See Kristin Purcell et al., Search Engine Use 2012, PEW INTERNET & AM. LIFE PROJECT, 18–23
(Mar.
9,
2012),
http://www.pewinternet.org/files/old-media/Files/Reports/2012/PIP_Search_Engine_Use_2012.pdf (finding that a majority of Americans surveyed do not like
having their online behavior tracked and analyzed).
327. Tom Garrubba, 5 Ways Health Data Breaches Are Far Worse Than Financial Ones,
HEALTHCAREIT NEWS (Nov. 10, 2014), http://www.healthcareitnews.com/news/5-ways-health-databreaches-are-far-worse-financial-ones (noting that data breaches may have deadly consequences in the
health care context); see Charles Ornstein, Small Violations of Medical Privacy Can Hurt Patients and
Erode
Trust,
NPR
(Dec.
10,
2015),
http://www.npr.org/sections/healthshots/2015/12/10/459091273/small-violations-of-medical-privacy-can-hurt-patients-and-corrode-trust
(providing an analogous example of the emotional and psychological harm that can result from a breach
of medical privacy); see also INSTITUTE OF MEDICINE ET AL., BEYOND THE HIPAA PRIVACY RULE 89
(Nass et al.eds. 2009) (explaining that a breach of private health information can result in a financial harm
because it may lead to discrimination in health insurance and employment).
328. See Maged N. Kamel Boulos & Steve Wheelart, The Emerging Web 2.0 Social Software: An
Enabling Suite of Sociable Technologies and Health Care Education, 24 HEALTH INFO. & LIBR. J. 2, 13
(2007) (noting that some users are wary about posting their personal information online because of data
mining).
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by distance—or medical conditions—can share intimate information.329 Patients
who live in remote areas or suffer from rare diseases can come together in a
seemingly private space to augment their medical care through hearing from others with similar symptoms or concerns.330 Social networks and online forums
are powerful tools to help people kick smoking habits,331 cope with chronic diseases,332 overcome depression,333 monitor their health, and express their frustration about their condition.334 However, the intrusion of third parties (whether
advertisers or medical researchers) without the patients’ consent can cause them
to flee social networks, denying them these potential benefits.335
A targeted subject also might suffer financial harm if her health information
is leaked by third parties. Because of cookies and tracking programs on computers and cell phones, user information about health concerns and symptoms can
readily be transmitted to insurance and credit card companies, without the research subject’s knowledge or consent.336

329. See, e.g., Jae Eun Chung, Social Networking in Online Support Groups for Health: How Online
Social Networking Benefits Patients, 19 J. HEALTH COMM.: INT’L PERSP. 639, 651–53 (2014) (explaining
that online support groups provide access to emotional and informational benefits that might otherwise be
unavailable due to geographic limitations or the rarity of a particular disease).
330. Id.
331. See Neill Bruce Baskerville et al., Effect of a Digital Social Media Campaign on Young Adult
Smoking Cessation, 18 NICOTINE & TOBACCO RES. 351, 355–57 (2015) (reporting that young adults had
greater cessation rates when using social media).
332. H. Alan Scott, How Instagram Helps Young People Cope with Cancer, VICE (Mar. 4, 2016),
http://www.vice.com/read/how-instagram-helps-young-people-cope-with-cancer.
333. See Tim Anstiss, How Social Media Is Supporting People with Depression, GUARDIAN (Apr. 26,
2012), http://www.theguardian.com/social-care-network/2012/apr/26/social-media-depression-support
(describing how social media provides an empathetic community to assist those suffering with depression).
334. See Felicity Morse, How Social Media Helped me Deal with My Mental Illness, BBC NEWSBEAT
(Feb. 18, 2016), http://www.bbc.co.uk/newsbeat/article/35607567/how-social-media-helped-me-dealwith-my-mental-illness (explaining how Yik Yak has provided a platform for patients to express their
frustrations anonymously).
335. See Purcell et al., supra note 326, at 23 (explaining that the majority of people strongly disfavor
having their online behavior analyzed); see also Bernard Lo & Lindsay Parham, The Impact of Web 2.0
on the Doctor-Patient Relationship, 38 J.L. MED. & ETHICS 17, at 21 (2010) (explaining how companies
that sell health products extract information from websites that do not have to abide by HIPPA Health
Privacy Rule). In addition to the benefits aforementioned in this article, other benefits that authors Lo and
Parham mention include better access to health information, better access to health care services, enhancement of patient decision-making, psychosocial benefits, and improved doctor-patient relationships. Id. at
19–20. There are also risks, such as that of receiving information that is inaccurate and the psychological
and social risks of learning of a diagnosis over the Internet instead of from a health care professional. Id.
at 20–21.
336. See Michael McFarland, Ethical Implications of Data Aggregation, SANTA CLARA U.:
MARKKULA CTR. FOR APPLIED ETHICS (June 1, 2012), https://www.scu.edu/ethics/focus-areas/internetethics/resources/ethical-implications-of-data-aggregation/ (warning that aggregated data can be transferred to a wide variety of marketers and may cause some people to be denied health insurance).
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VII. VIRTUAL CLINICAL TRIALS AND THE INTEGRITY OF THE RESEARCH
PROCESS AND ENTERPRISE
Virtual clinical trials may be beneficial for people who live in rural areas or
people who have a debilitating condition that inhibits them from traveling to research facilities.337 They may also be beneficial to patients who feel they spend
enough time in medical settings and do not want to make additional trips to a
hospital or doctor’s office or who have conditions that cause them to feel embarrassed in public.338 However, online medical studies do not provide the most
robust research results.339 It may be difficult to verify the accuracy and authenticity of the data.340 It may be difficult to verify that, for example, the person
entering the data is in fact the person participating in the trial, or that the person
is entering accurate and complete information. Monetary incentives increase the
possibility that people who do not suffer from the condition being studied will
attempt to participate in the trial.
Virtual clinical trials open the door for people to game the system. For
example, if an unqualified individual is rejected from a clinical trial initially
based on the answers he or she provides in a questionnaire, it is possible for that
person to create a new email address and therefore create another opportunity to
be selected. For a clinical trial that utilizes questionnaires to verify a participant’s identity, the participant would need to know enough information about
another person in order to be able to answer the questions. This would be fairly
simple for anyone with access to a public record database, the individual’s Facebook page, or if the person is a close friend or a family member (such as a teenage
child) with access to the intended participant’s information.
For a trial that requires medical records such as X-rays or that requires a
preliminary blood test—such as the REMOTE trial—it would be more difficult
to create a second opportunity to be selected, especially if the lab required the
participant to show identification before conducting the blood test. This extra
safeguard, however, would not work for virtual clinical trials developed for the
treatment of conditions which are difficult to measure physiologically, such as
depression and sleep apnea. In such trials, where no medical documentation of

337. See Sujay Jadhav, Virtual Clinical Trials: The Future of Patient Engagement?, APPLIED
CLINICAL TRIAL, at 1 (July 12, 2016), http://www.appliedclinicaltrialsonline.com/virtual-clinical-trialsfuture-patient-engagement (explaining the benefits of virtual clinical trials for patients with mobility issues).
338. See id. at 1 (identifying the ability of the patient to participate in the clinical trial from home as a
key advantage associated with virtual clinical trials); see also Richard G. Heimber, Cognitive-behavioral
Therapy for Social Anxiety: Current Status and Future Direction, 51 BIOLOGICAL PSYCHIATRY 101, 102
(2002) (explaining how patients with social anxiety disorder may feel humiliated or embarrassed in public).
339. See text infra accompanying note 341.
340. See Allison, supra note 9, at 898 (regarding self-reporting in the context of online medical research generally).
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the illness is required, it would be easy to create a false profile matching the
description of the condition—a person may simply search online for the symptoms associated with the condition.
When a research subject is not only recruited online, but also participates
in the study without the involvement of a traditional research facility, there is an
increased likelihood of physical harm and inaccurate conclusions about the experimental treatment. People who do not actually suffer from the conditions at
issue—or who are minors participating without their parents’ knowledge or consent—and are lured by monetary payment or a free smartphone, may be tempted
to take an inappropriate drug which might be harmful to them. If a serious side
effect or problem occurs, the person may report to their primary care physician
or local emergency room, instead of the trial investigators who might then be
unable to evaluate the potential dangers of the drug. On the other hand, a research subject may simply flush the drugs down the toilet and complete the
online form reporting no side effects, when serious side effects actually exist. If
pharmaceutical companies begin marketing treatments based on the results of
clinical trials completed entirely remotely, dangers arise not only to the research
subjects, but also to patients taking the drug after it receives approval as being
“safe and effective” based on misrepresentations by deceptive participants.341
Online medical research conducted with social network information may
also lead to flawed conclusions and can serve as the basis for protocols or therapeutics that are ineffective or unduly harm patients because the assumptions
made about an individual based on her or his social media profile may be
wrong.342 A person may lie about his or her age or weight on a social network
profile or use a decade-old photo; a person may post a status update minimizing
or exaggerating a health problem. If, for example, a biotechnology company was
doing research about the impact of alcohol use on people with diabetes, it might
choose to collect data on people who have searched the term “diabetes” on
Google or maybe “liked” the American Diabetes Association page on Facebook.
The biotechnology company might gauge this person’s use of alcohol based on
whether—and how many times—she or he checked in at a bar on Facebook, or
had a photo of himself online with a red cup in his hand (a common depiction
which police routinely use to show that someone under the age of 21 is drinking
illegally).343 However, such assumptions about a person could be completely
341. See Ashwaria Gupta, Fraud and Misconduct in Clinical Research: A Concern, 4 PERSP. IN
CLINICAL RES. 144, 146 (2013) (explaining how fraud can cause harmful medical products to be introduced).
342. See Naone, supra note 157 (describing a study that found that social networking data is not a
reliable source of data).
343. See Rupa S. Valdez et al., Beyond Traditional Advertisements: Leveraging Facebook’s Social
Structures for Research Recruitment, 16 J. MED INTERNET RES. 10 E243 (2014), https://www.jmir.org/article/viewFile/jmir_v16i10e243/2 (explaining that researchers target individuals based on the information
posted and provided on their social media page); see also KJ Lang, Facebook Turns into Big Brother,
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wrong: this person may have been going to a bar with friends and abstained from
drinking alcohol or could have been drinking a non-alcoholic beverage from the
damning red cup. Or the person who “liked” the American Diabetes Association
may be expressing solidarity for a friend and might not suffer from diabetes at
all.
With the financial incentives for participation and the reliance on self-reporting about the effects of the drug or device, there is the probability that participants will declare the intervention as beneficial without even taking the drug
or using the device.344 This may lead to FDA approval of dangerous interventions.345
Moreover, through the use of data aggregators that collect and sell thousands of pieces of information about people, researchers may be able to identify
and use a particular research pool—such as healthier people with a particular
medical condition—that makes their research results look better than if the research had been undertaken on a more diverse or random sample of individuals.346 This may lead to the marketing of treatments that pose more risks to the
end users than the researchers admit.
VIII. ISSUES REGARDING IRBS IN ONLINE MEDICAL RESEARCH
Some commentators may argue that the problems raised by online research
could be assuaged by an Institutional Review Board (IRB) evaluation of the research proposal.347 However, much of the research conducted online is not even
reviewed by an IRB.348 Also, a growing body of literature suggests that IRBs
LACROSSE TRIBUNE, Nov. 19, 2009, http://lacrossetribune.com/news/local/facebook-friend-turns-intobig-brother/article_0ff40f7a-d4d1-11de-afb3-001cc4c002e0.html.
344. See Christine Grady, Payment of Clinical Research Subjects, 115 J. CLIN. INVEST. 1681, 1684–
85 (2005) (noting concerns that subjects may deceive researchers in order to receive financial incentives).
345. See Gupta, supra note 243, at 146 (noting that the FDA plays a major role in preventing and
detecting fraud). And as Valerie Koch points out in the context of self-reporting for studies (which also
occurs in virtual clinical trials), “[w]ith no one to screen participants for eligibility, the possibility of selection and attrition-bias and mis-or over-reporting of symptoms and traits will likely increase, undermining the integrity of the data generated from such studies.” See Koch, supra note 248 at 53.
346. See Terry supra note 308 at 85–86. (explaining that data mining has become so sophisticated that
researchers can use it to reveal medical attributes based on web browsing history).
347. See Heidi Ledford, Death in Gene Therapy Trial Raises Questions About Private IRBs, 25 NAT.
BIOTECH. 1067 (2007) (noting that lack of oversight by IRBs can lead to botched clinical trials); U.S.
GOV’T ACCOUNTABILITY OFF., HUMAN SUBJECTS RESEARCH: UNDERCOVER TESTS SHOW THE
INSTITUTIONAL REVIEW BOARD SYSTEM IS VULNERABLE TO UNETHICAL MANIPULATION, 3 (Mar. 26,
2009) (explaining the importance of the IRB review board in their role of assuring patient safety and trial
reliability).
348. See John Carberry, Media Statement on Cornell University’s Role in Facebook ‘Emotional Contagion’ Research, CORNELL U. MEDIA REL. OFF. (June 30, 2014), http://mediarelations.cornell.edu/2014/06/30/media-statement-on-cornell-universitys-role-in-facebook-emotional-contagion-research/ (explaining that a professor who conducted a study on Facebook was not engaged in human
research that would require review by the Cornell Human Research Protection Program because he only
had access to the aggregated results of the study, and not individual identifiable data); see also Inder M.
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are not doing an appropriate job of assessing the risks associated with proposed
research projects, assuring the attainment of adequate informed consent, and protecting subjects from the risks.349 Online clinical trials present additional challenges for IRBs since they involve new processes (such as use of online health
information, electronic consent forms, and so forth) that have not been specifically addressed in the federal research regulations that IRBs are supposed to follow.350 In addition, IRBs may not appreciate the novel types of harms presented
by online recruitment, especially given the lack of transparency about data collection and use.351
There are two types of IRBs. Traditional, not-for-profit IRBs are generally
based at research institutions352 and universities.353 However, in the past these
traditional IRBs were unable to keep up with the increasing number of research
trial proposals resulting from an exponential growth in biotechnological and
pharmaceutical innovations,354 thus opening the door to private, for-profit IRBs

Verna, Editorial Expression of Concern and Corrections, 111 PROC. NAT’L ACAD. SCI. 10779, 10779
(2014) (expressing concern about the lack of institutional review board and the lack of an opt-out option
in the emotional contagion Facebook study).
349. See Ezekiel J. Emanuel et al., Should Society Allow Research Ethics Boards to be Run as ForProfit Enterprises?, 3 PLOS MED. 0941, 0941 (2006) (discussing the problems with IRBs and how they
are no longer properly reviewed and administered as they should be); see also Peter C. Williams, Success
in Spite of Failure: Why IRBs Falter in Reviewing Risks and Benefits, 6 IRB: ETHICS & HUM. RES. 1
(1984) (stating that IRBs often avoid weighing the risks and benefits of a trial and when they do, they are
often biased in favored of the trial moving forward); see also Sharona Hoffman, Regulating Clinical Research: Informed Consent, Privacy, and IRBs, 31 CAP. U. L. REV. 71, 84, 87, 89 (2003) (finding that most
informed consent forms do not provide useful explanations and recommending that IRBs require the forms
to be written in simple language); see also Donna Shalala, Protecting Research Subjects—What Must Be
Done, 343 NEW ENG. J. MED. 808, 809 (2009) (warning that many IRBs are not doing enough to protect
human subjects because the workload is excessive and they do not have enough resources); see also U.S.
GOV’T ACCOUNTABILITY OFF., supra note 347, at 1 (explaining the importance of the IRB Review Board
and their role of assuring patient safety and trial reliability).
350. See Stephanie Harriman & Jigisha Patel, The Ethics and Editorial Challenges of Interest-Based
Research, 12 BMC MED. 124 (July 15, 2014), http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-014-0124-3 (noting that there is a lack of national standards for IRBs regarding internet based research in the UK and USA); see also CONSIDERATIONS AND RECOMMENDATIONS
CONCERNING INTERNET RESEARCH AND HUMAN SUBJECTS RESEARCH REGULATIONS, WITH REVISIONS,
SEC’Y’S ADVISORY COMM. ON HUM. RES. PROTS., HEALTH & HUM. SERVS, at 14 (2013) (recommending
that the human subjects regulations be revised to address issues regarding internet research).
351. FTC, DATA BROKERS: A CALL FOR TRANSPARENCY AND ACCOUNTABILITY 57 (2015) (reporting
that overall transparency in the data collection industry is lacking and making recommendations to enhance transparency and consumer control).
352. See Ledford, supra note 347, at 1067.
353. U.S. GOV’T ACCOUNTABILITY OFF., supra note 347, at 1.
354. See Obasogie, supra note 47 at 72–73 (discussing that there were approximately six times more
clinical trials in the period of time between 2001 and 2004 than in the period of time between 1981 and
1985).
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to fill in the demand for faster review and approval of studies.355 These private
IRBs are organized either independently to review research studies or function
within private companies to review the companies’ own research studies.356 Research trials in traditional academic settings are now a minority when compared
to the growing number of trials in private pharmaceutical companies.357
Despite the crucial function that IRBs could play in protecting human research subjects, scholars have criticized both the traditional and external IRB
models as inadequate to ensure that research participants are adequately protected.358 On one hand, traditional IRBs are generally situated in the same research institution as the studies that are being conducted.359 Therefore, the researchers’ colleagues are often sitting on the IRB and are responsible for
approving or denying the studies.360 This raises the issue of whether or their
evaluations of studies are impartial.361 Similarly, an IRB that is funded by a
private company conducting a research study necessarily has an interest in making sure that studies are approved in order to increase profits.362 Even when
reviewing studies for another entity, for-profit IRBs are interested in approving
research quickly because for them it is a business transaction with the researchers
conducting the study.363
Scandals and investigations surrounding the inadequacy of the IRB model
have surfaced regarding both for-profit and traditional IRBs.364 Prestigious research institutions have had their studies and IRBs shut down due to gross inadequacies and lack of compliance with the relevant regulations.365 Investigative
355. See Ledford, supra note 347, at 1068 (addressing that researchers who also serve on non-profit
IRB boards are evaluating their colleagues’ research protocols which may increase the likelihood that they
will not perform critical evaluations).
356. Emanuel et al., supra note 349, at 942.
357. See id. (explaining that between 1994 and 2004, the number of clinical research trials conducted
in a traditional academic setting decreased from 63% to 26%).
358. See id. at 941 (explaining that not for profit IRBs are also subject to conflicts of interest that may
compromise the integrity of their evaluation); see also U.S. GOV’T ACCOUNTABILITY OFF., supra note
347 at 1 (investigating the IRB system and finding that independent IRBs are subject to unethical manipulation).
359. See Emanuel et al., supra note 349, at 941; see also Institutional Review Boards Frequently Asked
Question—Information Sheet, FDA (Jan. 25, 2016), http://www.fda.gov/RegulatoryInformation/Guidances/ucm126420.htm.
360. Emanuel et al., supra note 349, at 941.
361. Id.
362. See id. at 942 (explaining that commercial IRBs have a financial interest in approving trials,
creating a conflict of interest); see also Ledford, supra note 347, at 1067 (raising the concern of a system
in which the regulated is the sole funder of its regulator and the regulated has the power to change its
committee members to approve protocols to please customers).
363. Emanuel et al., supra note 349, at 942.
364. Id. at 942; Ledford, supra note 347.
365. See Emanuel et al., supra note 349, at 942 (discussing research institutions whose IRBs were shut
down after the death of research participants); see also Ledford, supra note 347, at 1067 (discussing nonprofits such as Hopkins, Duke, and the University of Colorado that have had their IRBs shut down).
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groups have been able to submit and obtain IRB approval for fake research studies purposely designed as posing a potential safety threat to research participants.366
Because of the problems inherent in the current IRB model, it is questionable whether IRBs can truly ensure the protection of research subjects in virtual
clinical trials. The Mytrus REMOTE trial underwent the review of two IRBs,
one a traditional academic IRB at the University of California, San Francisco
(UCSF) and the other a for-profit IRB, Western IRB (WIRB). 367 However, it is
questionable whether they were able to adequately protect the REMOTE subjects
due to the issues commonly associated with IRBs and the novel nature of online
trials. For example, WIRB’s history of approving risky studies is troubling.368
Although UCSF’s IRB was also involved in the review and approval process, it
is questionable whether its faster-than-usual approval process could have truly
taken into consideration all of the factors at play in the risk-benefit analysis and
protection of research subjects in a trial with unprecedented methodology.369
With scholars questioning the adequacy of the current IRB model to review
and approve traditional studies, it is unlikely that the added challenges to subject
protection inherent in the online research model will be given the consideration
they should receive when deciding to approve a study. In addition to the challenges posed by subjects being absent from a physical trial site—which could,
for example, provide immediate medical assistance in case of an adverse reaction
to a trial drug—the IRBs are ill-equipped to deal with the issues of electronic
informed consent, as well as the increased threats to privacy and confidentiality
of information arising from the online setting.370
IX. RECOMMENDATIONS
Virtual clinical trials present risks to participants and to the research process. Given the risks, several policy changes should be made.

366. See generally U.S. GOV’T ACCOUNTABILITY OFF., supra note 347.
367. Lisa Henderson, An Idea Whose Time Came: Patient-Facing Clinical Trials Are Finally Implemented a Decade Later http://www.appliedclinicaltrialsonline.com/idea-whose-time-came (last visited
Sept. 10, 2016).
368. See, e.g., Evans et al., supra note 213, at 39, 54, 56 (documenting WIRB’s accountability for
approving trials in which physicians were convicted in criminal investigations for putting the lives of
research subjects in danger and for making false statements to the FDA); see also Ledford, supra note
347, at 1067 (noting that bioethicists were concerned about WIRB following the death of a research participant in a WIRB approved trial).
369. See Henderson, supra note 367. In an interview, then Mytrus’ Chief Operating Officer, Anthony
Costello, explained that the approval process for the trial was rather fast, despite the amount of information
the IRBs had to review, and despite the fact that IRBs usually operate slowly. Id.
370. James C. Hamilton, The Ethics of Conducting Social Science Research on the Internet, 46
CHRON. HIGHER EDUC. B6 (1999) (reporting that many IRBs had reviewed proposals for online research
but few of them had guidelines or the technical knowledge necessary to evaluate the proposals properly).
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A. Online Health Information Should Be Treated as Confidential
Confidentiality laws should be adopted by the states to ban the unauthorized
collection, marketing or use of health information that a person discloses on the
web. The federal regulations adopted under HIPAA, should be extended similarly to cover any online health information, even if it is not in the hands of a
health care provider or a health care institution.
B. Recruitment Should Be Exclusively Consumer-Initiated
Authorization for participation in research should be by an explicit optin.371 Recruitment for medical research should not be based on health information revealed through a person’s online activities or the imputation of health
status through non-health data (such as posting about going to fast food restaurants or watching cable television). Instead, a clinical trial website should be
created that people can go to on their own to express interest in receiving information about clinical trials, including virtual clinical trials. In order to strike a
balance with researcher’s legitimate need to enroll subjects into research trials,
models such as the one developed by TrialX (where people can use Twitter to
indicate that they would like to receive information about clinical trials) would
be acceptable.372
Furthermore, people who wish to keep their medical conditions confidential
should not be subject to the anxiety-inducing process of suddenly being solicited
for a virtual or in-person clinical trial for those medical conditions.373 Therefore,
the Federal Trade Commission should investigate more broadly instances of unsolicited recruitment for studies through the surreptitious collection of people’s
medical information and consider the marketing of health information or inferred
health status a form of consumer fraud.
C. Researchers Should Be Treated as Fiduciaries of Research Subjects
Research subjects in virtual clinical trials currently lack the legal protections afforded to subjects in traditional research trials conducted by doctors in

371. Research suggests that people are largely in favor of an opt-in consent process, for example in
research undertaken on biobank samples. See Christian M. Simon et al., Active Choice but Not Too Active:
Public Perspectives on Biobank Consent Models, 13 GENETICS IN MED. 821, 826 (2011) (presenting a
survey that found that a majority of focus group participants preferred an opt-in method).
372. @TrialX, TWITTER, https://twitter.com/trialx (last visited Dec. 9, 2016); see also A New Twitter
Application by TrialX Lets You Find Clinical Trials That Match Your Health Conditions, FIERCE BIOTECH
(Apr. 24, 2009, 10:16 am), http://www.fiercebiotech.com/biotech/a-new-twitter-application-by-trialxlets-you-find-clinical-trials-match-your-health.
373. See StopCorp.Crap, Comment to Acurian, Inc: Unsolicited Mail, COMPLAINTS BOARD,
http://www.complaintsboard.com/complaints/acurian-inc-pennsylvania-c574582.html (last visited Jan.
22, 2017) (showing examples of solicitation from clinical trials to persons who did not know that their
medical conditions, or their child’s medical conditions, were known).
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medical institutions.374 This could be addressed by a legal policy holding researchers to be fiduciaries. Researchers have several things in common with
doctors which would justify considering them fiduciaries.375 Those factors include the research subject’s ignorance of the research and their need to entrust
their well-being to researchers, the researcher’s superior knowledge of the subject matter and the consequences of research,376 and the fact that the research
subject may consider his or her relationship with the researcher the same as that
of his or her relationship with a doctor.377 Holding researchers to be fiduciaries
would allow subjects to have legal recourse against researchers on a fiduciary
duty basis, for example, as a result of harm caused to the subject from his or her
participation in an unduly risky virtual clinical trial.378
D. The Electronic Informed Consent Process Should Include Additional
Information and Safeguards
Electronic informed consent should not be used without access to a person
to answer questions. In addition, the process should have a means of assuring
the identity of the person who is signing the form and also of the person participating in the study.
The consent process should also provide the subject with the ability to limit
the sharing of information gathered from the study. Electronic informed consent
forms should give subjects full control over the sharing of study data, that is,
whether they want their data to be used only by the researchers conducting the

374. U.S. DEPT. HEALTH & HUMAN SERV., SEC’Y’S ADVISORY COMM. ON HUMAN RESEARCH PROT.,
supra note 147 (recommending revisions to the federal regulations because they do not adequately address
internet research issues); see also Valerie Gutmann Koch, A Private Right of Action for Informed Consent
in Research, 45 SETON HALL L. REV. 173, 176 (2015) (stating that research subjects often do not have a
private right of action because most jurisdictions do not recognize a legal relationship between the researcher and the research subject).
375. See Richard S. Saver, Medical Research and Intangible Harm, 74 U. U. CIN. L. REV. 941, 990,
(2006); see also Andrew Fichter, The Law of Doctoring: A Study of the Codification of Medical Professionalism, 19 HEALTH MATRIX: J. L.-MED. 317, 365–368 (2009) (arguing that researchers owe fiduciary
duties to their subjects in a way that is similar to what is required of a doctor); see also Paul B. Miller &
Charles Wijer, Fiduciary Obligation in Clinical Research, 34 J. MED. & ETHICS 424, 424, 428, 437 (2006)
(arguing that the researcher-subject relationship should be considered fiduciary as a matter of law).
376. See Fichter, supra note 375, at 367 (stating the gap in knowledge investigators and participants
possess inevitably exists, and that participants should not be responsible for their own protection).
Whereas some legal commentators argue that researchers should be held to owe fiduciary duties to research subjects, other legal scholars are more skeptical, arguing that fiduciary duties are not compatible
with the need for researchers to adhere to the research protocol; see, e.g., E. Haavi Morreim, The Clinical
Investigator as Fiduciary: Discarding a Misguided Idea, 33 J.L. MED. & ETHICS 586, 588 (2005) (maintaining that researchers are not fiduciaries, as many research trials do not involve medical care and each
role in research must be individually considered).
377. See Saver, supra note 375, at 941–1012, 967–71, 990–92.
378. See Moore v. Regents of the Univ. of Cal., 793 P.2d 479, 483 (Cal. 1990) (finding that the doctorresearcher breached his fiduciary duty patient-participant and holding the doctor liable).
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study, or if they would also consent to the use of their data in an additional specific study that is explained in detail.379 There should be no blanket consent for
unspecified future research.
Informed consent policies for virtual clinical trials should also address the
issues of data security inherent when conducting the clinical trial process entirely
online and should disclose to subjects the consequences that can result from a
data breach. It should clearly inform the subject of the potential issues that can
arise as a result of the use of trial drugs—regardless of whether such drugs had
been previously approved for the same or another condition.
E. Data Security Measures Should Be Taken by Virtual Clinical Trial
Developers to Ensure the Protection of Sensitive Metrics and Personal
Information of Research Participants
Not only is medical information collected, but some medical apps used in
research can turn on a subject’s microphone and track geolocation.380 As virtual
clinical trials adopt smartphone platforms, more sensitive information about research subjects will be collected, demanding strict data security protocols.381
F. Drugs Should Not Be Approved Based Only on the Results of a Virtual
Clinical Trial
Because the virtual clinical trial’s data is self-reported, there is no way to
assure the accuracy of such data. Even the inventors who patented the virtual
clinical trial process believe that “the internet based trial method is most suitable
when the intervention is safe, the medical disorder can be confirmed by remote
means and the outcome measures can be applied by using electronically transmissible technologies.”382 Also, to prevent potentially dangerous drugs from entering the market, some type of in-person clinical trial should follow the virtual
clinical trial to validate the virtual trial’s results.

379. Sage Bionetworks has developed an electronic informed consent form for ResearchKit’s mPower
Parkinson’s disease app for iPhone. Although the app has an option for the sharing of study data with
“Sage Bionetworks and its partners and qualified researchers worldwide” or to “only share [the] data with
Sage Bionetworks and its partners” it does not specify who the partners are (their affiliations, whether
they have any financial interests in the study, etc.) and it does not provide for an option to only let the
researcher conducting the study (Sage Bionetworks) use the data. See Brian M. Bot et al., The mPower
Study, Parkinson Disease Mobile Data Collected using ResearchKit, 3 SCIENTIFIC DATA 1, 2 (2016),
http://doi.org/10.1038/sdata.2016.11.
380. See Blenner et al., supra note 113, at 1051 (reporting the results of a study that found that some
diabetes apps could activate the microphone, track locations, and turn on the camera).
381. See id. (stating that the sharing of sensitive information from most medical apps is not currently
prohibited by the Health Insurance Portability and Accountability Act).
382. McAlindon et al., supra note 65 at 487.
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G. IRBs Should Be Given Explicit Directives in the Federal Research
Regulations for Dealing with Virtual Clinical Trials
As technology changes the way in which research is conducted, IRB oversight will have to be implemented in a way that addresses novel challenges—
such as the need for proper identification of the user-subject and protecting the
confidentiality of the electronic data, and ensuring that subjects’ health will be
protected. In addition, IRBs should be required to analyze whether privacy has
been breached in recruitment or data analysis and to determine that adequate
measures have been taken to protect cyber-security. The IRBs should also be
trained to recognize the novel psychological, physical and financial risks posed
by virtual clinical trials.
H. Any Federal or State Law Protecting Subjects in Virtual Clinical Trials
Should Include a Private Cause of Action
The current federal research regulations do not provide a private cause of
action, thwarting recourse for even egregious violation of the regulations.383 A
preferable model could be the California approach which gives research subjects
the possibility of suing for violation of law regulating research, including inadequate informed consent.384
X. CONCLUSION
The purpose of research regulations is to: (1) protect people’s choice of
whether or not to participate in research; (2) assure that subjects will not be
harmed by the research and that the benefits outweigh the risks; (3) protect research subjects’ confidentiality; (4) protect the public by assuring that the research is adequate; and (5) ensure trust in the research enterprise so that people
will continue to participate in research. However, the current conduct of online
researchers fails to meet these goals and instead circumvents the very protection
the regulations were meant to offer. Informed consent is likely to be overlooked
and is difficult to obtain in the online setting, privacy is likely to be breached,
and the study methodologies may not adequately assure the safety of treatments
investigated in the digital milieu.
The internet has transformed relationships and social institutions in profound ways. Dating, education, marketing, and communicating are all stunningly different in the post-Facebook era than they were a decade ago. Physicians, pharmaceutical companies, and biotechnology companies are all taking

383. See 45 C.F.R. § 46.113 (1991) (stating that violation of the regulations warrants suspension of
institutional review board approval rather than a private cause of action for the research subjects).
384. In California, the Protection of Human Subjects in Medical Experimentation Act makes researchers who conduct research on human subjects without informed consent liable to the subjects for damages.
CAL. HEALTH & SAFETY CODE § 24176 (West 2003).
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advantage of social networks and the web to pursue online medical research.385
Such research has risks as well as benefits, and it is important to employ traditional research protections for prior review, voluntary and un-coerced consent,
assurances that the benefits of the research outweigh the risks, and protection of
confidentiality.

385. See Allison, supra note 9, at 895 (detailing dozens of companies who are using social media to
recruit patients and conduct clinical trials).

